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SUMMARY

We undertook a comprehensive proteogenomic
characterization of 95 prospectively collected endometrial carcinomas, comprising 83 endometrioid and
12 serous tumors. This analysis revealed possible
new consequences of perturbations to the p53 and
Wnt/b-catenin pathways, identified a potential role
for circRNAs in the epithelial-mesenchymal transition, and provided new information about proteomic
markers of clinical and genomic tumor subgroups,
including relationships to known druggable pathways. An extensive genome-wide acetylation survey
yielded insights into regulatory mechanisms linking
Wnt signaling and histone acetylation. We also characterized aspects of the tumor immune landscape,
including immunogenic alterations, neoantigens,
common cancer/testis antigens, and the immune
microenvironment, all of which can inform immuno-

therapy decisions. Collectively, our multi-omic analyses provide a valuable resource for researchers
and clinicians, identify new molecular associations
of potential mechanistic significance in the development of endometrial cancers, and suggest novel
approaches for identifying potential therapeutic
targets.
INTRODUCTION
Endometrial carcinoma (EC) is the sixth-most-common cancer in
women globally (Bray et al., 2018), with an estimated 61,880 new
cases and 12,160 deaths in the United States in 2019 (Siegel
et al., 2019). Most women diagnosed with EC have early-stage
disease and favorable outcomes; this is particularly true for
well-differentiated cancers with endometrioid histology (Amant
et al., 2005). However, there is a subset of low-grade, earlystage, well-differentiated endometrioid tumors in which unexpected recurrences and poor outcomes do occur. Clinical
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outcomes worsen considerably for women with recurrent or
advanced disease and for women diagnosed with a clinically
aggressive histologic subtype of the disease, such as the serous
histotype (Siegel et al., 2018; Walker et al., 2009). EC is one of the
few human malignancies for which mortality is increasing (American Cancer Society, 2017), which underscores the urgent need
to develop more effective strategies for the diagnosis and treatment of this disease.
The Cancer Genome Atlas (TCGA) recently published a
comprehensive genomic study of serous and endometrioid EC
and reported four genomic subtypes: POLE, a rare ultramutated
subtype with endometrioid histology and good prognosis; microsatellite instability (MSI), a hypermutated endometrioid subtype;
copy-number (CNV) low, which consists of most of the rest of the
endometrioid cases; and CNV-high, comprised of all serous and
the most aggressive endometrioid cancers (Kandoth et al.,
2013). To improve our understanding of the functional impact
of the genomic alterations characterized by TCGA, we conducted an extensive multi-omic characterization of EC samples
and appropriate normal tissues from a prospective cohort of
95 EC patients, under the auspices of the National Cancer Institute’s Clinical Proteomic Tumor Analysis Consortium (CPTAC).
Integrated measurements of DNA, RNA, proteins, and posttranslational modifications (phosphorylation and acetylation)
were used to identify novel regulatory relationships and potential
avenues for identifying therapeutic targets.
RESULTS
Overview of the Proteogenomic Landscape
We obtained 95 prospectively collected EC tumors (83 endometrioid and 12 serous) and 49 normal tissue samples for
multi-omic characterization. The clinical and pathological characteristics of the tumors are summarized in Table S1. Each sample underwent whole exome, whole genome, and total and
miRNA sequencing, along with DNA methylation analyses. In
addition, the relative levels of the proteins and post-translational
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modification (PTM) sites across the tumor and normal tissue
samples were quantified (Figure 1; Figure S1A) by using isobaric
labeling with a universal reference strategy (Mertins et al., 2016;
Zhang et al., 2016a), applying a stringent 1% false discovery rate
(FDR) cutoff at the protein level. The methods and results, quantification results, and normalization methods were carefully evaluated to confirm data quality (STAR Methods; Figures S1B–1L).
Processed data tables are available in Table S2, the cptac Python package, and LinkedOmics (Vasaikar et al., 2018); raw
data are available via the Genomic Data Commons (GDC) and
CPTAC Data Portal (STAR Methods).
Tumors were classified into the four genomic subtypes outlined in the TCGA EC landmark study (Kandoth et al., 2013):
POLE, MSI, CNV-low (also called endometrioid-like), or CNVhigh (also called serous-like) (STAR Methods; Figure 1; Table
S3). Note that the endometrioid histological subtype mostly segregates into the POLE, MSI, and CNV-low genomic subtypes,
whereas CNV-high consists of all serous tumors and a small
number of endometrioid tumors. Our cohort included 7 POLE,
25 MSI, 43 CNV-low, and 20 CNV-high tumors (Figure 1). Protein
and PTM levels differing between genomic subtypes (FDR <
0.05, Wilcoxon rank-sum test) are shown in Figure 1 (also see
Table S3). Functional analysis of protein levels by subtype indicated a relative downregulation of cell cycle proteins and phosphorylation in the CNV-low subtype, associated with an increase
in cell transport and metabolism proteins. Furthermore, phosphorylation on proteins related to DNA double-strand break
repair was decreased without a corresponding protein level
change (Table S3). Conversely, the CNV-high subtype had
increased phosphorylation on proteins involved in ATM
signaling. As expected, mismatch repair was generally suppressed in POLE, MSI, and CNV-high subtypes. Serous samples
have the highest upregulation of ribosome biogenesis, which has
been associated with poor cancer prognosis (Pelletier
et al., 2018).
Roughly 61% of all somatic mutations were found in the seven
POLE tumors (n = 32,340; 32,188 point mutations and 152

Figure 1. Proteogenomic Summary of the Cohort
Samples are ordered by genomic subtype and then by histology. Representative pathways are shown for genes with the greatest variation between subtypes. For
each sample, we display mutation load, copy number indices (at both global and arm levels), and mutation status in SMGs.
See also Figure S2; Table S3.

indels), five of which harbored the known recurrent hotspot mutation P286R in the catalytic subunit of DNA polymerase epsilon
(POLE). MSI tumors carried 88% of all indels in the cohort
(n = 5,061), and a focused analysis on microsatellite indels found
higher mutation rates for significantly mutated genes (SMGs) in
this subtype than previously reported, including PTEN (92%),
ARID1A (76%), and RPL22 (64%) (all FDR = 0, STAR Methods).
We additionally identified INPPL1 (56%), KMT2B (56%), and
JAK1 (44%) as putative SMGs in the MSI subtype, which were
not reported in the TCGA study (Figure S2A) (FDR = 0, 0.001,
and 6.4e-07, respectively, STAR Methods). Of note, all of the
JAK1 frameshift mutations were in MSI samples and were
derived from microsatellite indels (Figure S2B). JAK1 mutations,
which are associated with high tumor grade (Figure S2C), could
promote immune evasion in MSI samples (see Antigen Processing and Presentation Deficiency). Using a conservative proteogenomics approach (STAR Methods), we were able to confirm
206 putative somatic coding variants at the protein level, along

with 85 novel splice junctions (Table S4). The set of genes
frequently altered by copy number variation, including ERBB2,
CCNE1, FGFR3, and IGF1R, was similar to that in the TCGA
cohort.
In summary, the genomic characteristics of our prospective
EC cohort are consistent with those of the prior TCGA study,
with the exception of some increases in observed mutations
that could be attributable to differences in the DNA sequencing
platforms used.
Somatic Drivers Impact the Cancer Proteome and
Phosphoproteome
We examined the impact of somatic driver mutations on the
proteome and phosphoproteome, both cis-acting (acting on
the gene in which the mutation occurs) and trans-acting (acting
on other genes), focusing on 18 SMGs (STAR Methods). Of
these 18 SMGs, we identified 7 and 6 genes with cis and trans
effects, respectively (FDR < 0.05, Wilcoxon rank-sum test). We
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Figure 2. Effects of Somatic Mutations
(A) Cis and trans effects of mutations in EC SMGs. Affected proteins and phosphoproteins are grouped by pathway.
(B) Effects of missense and truncation mutations.
(C) Effects of CTNNB1 mutations.
(D) p53 binds DNA as a tetramer. Highlighted in red is a mutation-phosphosite cluster that directly affects the DNA binding domain of p53.
(E) Effects of TP53 mutations.
See also Figure S3.

found a total of 143 trans associations (71 at the protein level
and 72 phosphosites) spanning 49 interacting proteins. The
largest trans associations at both protein and phosphorylation
levels involved mutations in ARID1A, TP53, and CTNNB1, likely
in connection with their known regulatory roles (STAR Methods,
Figure 2A) (Bailey et al., 2018). As expected, in tumors with
TP53 mutations, we observed an increase in levels of p53 itself,
as well as in other proteins in the p53 pathway (e.g., CDK1 and
CHEK1). Through a similar process, we observed reduced
levels of phosphorylated ARID1A, MAP3K4, KMT2D, and
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INPPL1 in cis but increased levels of phosphorylated b-catenin
and p53 (Figure 2A).
By assessing truncating and missense mutations separately,
we detected distinct effects of the two mutation types on RNA,
protein, and phosphoprotein levels of several key genes (Figure 2B). Missense mutations can either promote or stifle gene
expression at the protein level, though this was rarely reflected
at the RNA level. As observed previously, there was an increase
in protein levels of b-catenin and p53 associated with known hotspot mutations (Gao et al., 2017; Suad et al., 2009) and a

decrease in PIK3CA and SYNE1. The effect of mutations on protein levels in our cohort tended to correlate well with phosphoprotein levels; taken together with the lack of variance in RNA
levels, this suggests strong translational and protein-stabilityrelated regulation, especially as these patterns persist even
when the hypermutated POLE and MSI tumors are removed
from the analysis (Figure S3A). Truncating mutations, meanwhile, led to decreases in ARID1A, INPPL1, JAK1, PTEN, and
RBM27 protein levels.
Effects of CTNNB1 Mutations
Exon 3 of CTNNB1, an SMG that codes for the protein b-catenin, is known to have several mutational hotspots at or near
phosphorylation sites that, when altered, lead to constitutive
b-catenin activation. Altered b-catenin is thought to drive
tumorigenesis in multiple cancers (Gao et al., 2017), notably
colorectal cancer (Wong and Pignatelli, 2002) and EC (Machin
et al., 2002). EC patients with low-stage, low-grade endometrioid tumors, who would normally have a good prognosis,
have a much higher chance of recurrence when CTNNB1 is
mutated, although the reason for this is unclear (Kurnit et al.,
2017; Myers et al., 2014). To understand the underlying mechanism, we analyzed the impact of hotspot CTNNB1 mutations,
which were found in 23 tumors in the cohort, on the proteome
and phosphoproteome (Figure 2C; Figure S3B). Of these 23 tumors, all but two are CNV-low or MSI, none are higher than
grade 2, and only three are stage III; the rest are stage II or
lower. We observed increased protein and phosphoprotein
levels of known physically interacting complex partners and upstream regulators of b-catenin in tumors with hotspot mutations
(Figure 2C; Figures S3C and S3D). b-catenin, APC, and AXIN1
form the b-catenin destruction complex that serves as a major
mediator within the Wnt signaling pathway; APC and AXIN1
protein levels were also upregulated in CTNNB1-mutated tumors (Figure S3E). In fact, tumors with CTNNB1 hotspot mutations had higher Wnt signaling pathway activity (STAR
Methods) than did their WT MSI and CNV-low counterparts
(Figure S3F) (p = 2.5e-3, Student’s t test). This study marks
the first instance of co-identification of CTNNB1 complex partners and upstream regulators via global mass spectrometrybased proteomics.
We used HotSpot3D (Niu et al., 2016) to assess whether 3D
proximity of a mutation to a PTM can affect the protein. Indeed,
the CTNNB1 exon 3 hotspot region (centered at S33) formed a
3D cluster, consisting of the phosphosites at Y30, S33, and
T40, as well as recurrent mutations at D32 and G34 (Figure 2C).
This suggests a possible reason why mutated non-phosphosite
residues in this region result in the same phenotype as mutations
directly in the phosphosite codons.
An alternative upstream mechanism for b-catenin overexpression in EC involves the deactivation of APC, which normally
promotes phosphorylation of b-catenin, leading to b-catenin
degradation. In the 11 tumors without mutation-phosphosite
overlaps in CTNNB1 but with mutations in APC, we observed
reduced levels of APC and higher levels of b-catenin, although
this increase was much less pronounced than that observed
in tumors with CTNNB1 exon 3 mutations. Conversely, when
considering CTNNB1 exon 3 mutants on their own, we

observed regular protein levels of APC (Figure S3E). By accounting for the proximity of mutations to phosphosites, we
found that our results were consistent with the two mutually
exclusive mechanisms for increasing b-catenin levels: either
somatic mutation in CTNNB1 hotspots or mutational inactivation of APC.
To summarize, we observed co-regulation of CTNNB1 and key
interacting proteins, including reciprocal activating mutations of
CTNNB1 and inactivating mutations of APC as modulators of
b-catenin levels, as well as providing mechanistic insight into
the roles of specific CTNNB1 mutations.
Effects of TP53 Mutations
TP53 is the most commonly mutated gene in human cancers
(Hainaut and Pfeifer, 2016). TP53 mutations were observed in
23 tumors in our cohort, including all serous carcinomas. Instead
of grouping all TP53-mutated tumors together and looking for a
single molecular phenotype, we segregated them by mutation
type and location. We identified several proteomic and phosphoproteomic signatures that are consistent with the emerging hypothesis of neofunctionalization for hotspot missense mutations
(Kim et al., 2015; Lang et al., 2004). Eleven tumors harbored
missense mutations in a spatially clustered hotspot in p53’s
DNA-binding domain (Suad et al., 2009) (Figure 2D), which led
to elevated protein levels (Figure 2E). This cluster included the
highly recurrent mutated residues R248 and R273 that interfere
with p53’s ability to bind DNA (Mello and Attardi, 2013) and
cause cascading dysregulation of downstream proteins
including AURKA (Nikulenkov et al., 2012) and XRN2 (p = 7.8e06, t test), an exoribonuclease that promotes the epithelialmesenchymal transition (EMT) and metastasis (Zhang et al.,
2017a). A variety of truncating TP53 mutations were found in
seven tumors. Although the observed truncating mutations did
not alter p53 protein levels (p = 0.082, t test), they were nevertheless associated with downstream effects, including increased
phosphorylation of PLK1-T210, which triggers recovery from
the G2 DNA damage checkpoint (Mac
urek et al., 2008; Paschal
et al., 2012) and mitotic entry (Vigneron et al., 2018). Indeed, tumors with truncating TP53 mutations are enriched for mitotic
cells; among 14 mitotic marker proteins (Ly et al., 2017), most
showed increased levels in tumors with TP53 mutations (Figure S3G). This is likely caused by aberrant p53 function in mutant
samples allowing cells to enter mitosis despite having DNA damage that would be detected in TP53 WT tumors. A third subset of
p53 interacting proteins, including CDK1, XPO1, and TPX2, was
dysregulated whenever TP53 was mutated regardless of the
specific type of mutation.
Although TP53 hotspot mutations have been extensively studied, including the likely differential functional consequences between truncating mutations and neofunctionalization hotspot
mutations, the actual effects of distinct TP53 mutations on the
protein level of trans-interacting proteins in specific cancers
have not been well described prior to this study. The mutationtype-specific effects described above appear to be unique to
EC; we examined the CPTAC data for ovarian and colon cancer,
where TP53 mutations are very common, but observed no
change in AURKA, CDK1, XPO1, or STK11 protein levels associated with the type of TP53 mutation (Figure S3H).
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Regulation of Histone Acetylation
Characterization of the patient-derived cancer tissue acetylome
has been limited. Similar to previous work in cell lines (Choudhary et al., 2009, 2014), we observed an enrichment in EC tumors
of acetylated proteins involved with splicing, RNA transport, protein synthesis and degradation, and metabolic pathways (Figure S4A). We observed a large degree of heterogeneity in histone
acetylation patterns across tumor samples (Figure S4B) but no
strong association with discrete genomic subtypes or clinical
features. We found positive associations between BRD3 protein
levels and several H2B N-terminal acetylation sites, as well as
negative associations between SIRT1, SIRT3, BRD4 protein
levels, and H3K27 and K36 acetylation levels (Figure 3A; Figure S4C). This suggests that BRD3 can potentially bind to H2B
N-terminal acetyl residues, which could make them less accessible to erasers and prevent their deacetylation. In addition,
negative correlations between SIRT1 and SIRT3 and H3 acetylation indicate that these histone deacetylases couldregulate
H3K27 and K36 acetylation levels. Overall, we identified 322
sites that are upregulated (n = 216) or downregulated (n = 106)
in tumor samples as compared with normal samples (Figure 3B;
STAR Methods).
We assessed how histone acetylation is affected by mutations
in EC and found upregulation of H2B N-terminal acetylation sites
K16, K20, and K24 in samples with CTNNB1 hotspot mutations
(Figures 3C and 3D; Figure S4D) and upregulation of H3 sites,
including K27 and K36, in both ARID1A- and KRAS-mutated
samples (Figures 3E and 3F). Previous reports have underscored
the importance of acetylation-driven mechanisms in Wnt
signaling (Alok et al., 2017; Lévy et al., 2004; Wolf et al., 2002);
we observed increases in BRD3 and SIRT1 protein levels in
CTNNB1 hotspot mutants that were consistent with the
observed effects of CTNNB1 hotspot mutations on H2B acetylation (Figure S4D). Additionally, we observe an upregulation of
gene expression in several Wnt pathway genes in samples with
high H2B acetylation levels (Figure S4E).
We identified 56 downregulated sites and 16 upregulated sites
in the CNV-low subtype as compared with the CNV-high subtype
(Figure S4F). One upregulated site, FOXA2-K274, has been
found, when deacetylated, to decrease FOXA2 stability (van
Gent et al., 2014). FOXA2 itself has been linked to increased
cell proliferation and invasion in colon cancer (Wang et al.,
2018). Hence, the increased FOXA2 acetylation could indicate
improved stability and activity of the protein, which might promote proliferation of CNV-low EC tumors. However, FOXA2
has also been found to inhibit metastasis in lung adenocarcinomas (Li et al., 2015; Tang et al., 2011), so further work is
required to define the role of FOXA2 acetylation in EC.
Our observations highlight the heterogeneity of the acetylome
in EC and the potential impact of mutations in SMGs on histone

acetylation levels, which could have overarching effects on tumor biology via newly identified interactions with the Wnt
signaling pathway, BRD proteins, and methylation proteins.
The extent to which these relationships are specific to EC or a
general effect of CTNNB1 mutations on histone acetylation will
require similar comprehensive studies of the acetylome in other
cancers. Additionally, we identify tumor-specific upregulation of
acetylation levels in translation elongation factors and methyltransferase proteins, as well as a potential role for FOXA2 in
the more aggressive CNV-high subtype.
Multi-omic Analysis Reveals DNA Methylation and
Somatic Copy Number Alteration Drivers
DNA methylation (DNAme) analysis revealed elevated genomewide CpG island DNAme in MSI tumors (Figure S5A), which is
consistent with previous reports (Horowitz et al., 2002; Tao
and Freudenheim, 2010). Methylation-silenced genes include
MLH1, an essential component of the DNA mismatch repair
(MMR) machinery (Figure 4A; Figure S5B). We also found that
several HOX family members were silenced by DNAme (Figure 4A). HOX genes have been previously connected to double-strand DNA break (DSB) repair (Feltes, 2019). We identified
an anticorrelation between HOX protein levels and H2AX protein
phosphorylation, a molecular indicator of DSBs. There has been
speculation that tumors with MMR defects are also more prone
to have DSBs (Nowosielska and Marinus, 2008). Our results suggest that increased methylation of the relevant factors could
partially account for the dampening of both of these DNA repair
pathways (Figure S5B).
Integrated analysis of somatic copy-number alterations
(SCNAs) with transcriptomic and proteomic data revealed that
14% of all SCNAs were associated with cis effects (FDR <
0.01, Spearman’s test). The SCNAs with the strongest trans effects (i.e., demonstrating a broader impact on global gene
expression) were centered on chromosomes 1q, 3q, 4q, and
20q (Figure 4B; Table S5) and were identified in the CNV-high
tumors (Figure S5C). Proteins whose levels were positively
associated with 3q amplification included DNA replication and
cell cycle proteins, such as cyclin-dependent kinases and minichromosome maintenance family members (FDR < 0.05, hypergeometric test, Figure S5D). The pathways most impacted by 4q
loss included cytoskeleton and cilium assembly (Figure S5E);
interestingly, ciliopathy has recently emerged as an indicator of
tumor onset (Sánchez and Dynlacht, 2016).
Chromosome 1q amplification was the only SCNA commonly
observed in both MSI and microsatellite stable (MSS) tumors.
Consistent with previous findings (Horowitz et al., 2002; Tao
and Freudenheim, 2010), we confirmed that 1q amplification
was anticorrelated with p53 pathway activity (p < 0.01, Pearson’s
correlation, Figure 4C; STAR Methods). Because TP53

Figure 3. Acetylation
(A) Associations of the levels of key acetylation enzymes with histone acetylation sites.
(B) Change in acetylation levels between tumor samples and normal endometrium samples. The horizontal line denotes an FDR cutoff of 0.05, and the vertical
lines denote a fold change of 0.4. Grey points represent sites whose acetylation change is explained by a change in protein levels.
(C) Association between histone acetylation sites and mutated SMGs. The acetylation change is shown for the most significant site in each histone protein.
(D–F) Acetylation-level changes in specific histone sites in WT and mutated samples for CTNNB1 (D), ARID1A (E), and KRAS (F).
See also Figure S4.
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Figure 4. Proteomics Data Reveal SCNA and DNA Methylation Drivers of Tumor Progression
(A) MLH1 and HOX family genes are directly affected by DNA methylation. Samples are ranked from lowest (left) to highest (right) DNA methylation levels.
(B) Effects of SCNA on mRNA and protein levels. Top: copy number correlation with mRNA (left) and protein (right). Positive and negative correlations are
indicated in red and blue, respectively. Bottom: the frequency of correlations. Blue bars represent copy number correlation with mRNA (left) and protein (right),
and black bars represent copy number correlation to both mRNA and protein.

(legend continued on next page)
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mutations are rare in MSI tumors, we speculated that 1q amplification could be a major mechanism in repression of p53
pathway activity in these tumors. We confirmed that the mRNA
levels of MDM4, a gene located in 1q that codes for a previously
reported p53 inhibitor (Depreeuw et al., 2017), were increased
along with its copy number (p < 0.01, Spearman’s correlation).
However, we did not detect the MDM4 protein, likely due to
low abundance. To identify potential p53 pathway inhibitors
with protein evidence, we ranked all genes based on the anticorrelation between their protein level and p53 activity and highlighted the ones with SCNA cis effects (Figure 4D). As expected,
genes mapping to 1q exhibited stronger negative correlation
with p53 pathway activity than did other genes (p = 3.4e-4,
STAR Methods). That negative correlation was even stronger
for 1q genes with SCNA-protein correlation than for other 1q
genes (p = 1.1e-4, GSEA), suggesting a role for SCNA-driven
overexpression of 1q genes in repressing p53 pathway activity.
The top-ranked genes included many histone modifiers
including SETDB1, SDE2, PARP1, and GATAD2B (Figures 4D
and 4E). SETDB1, the strongest candidate, showed
anticorrelation to p53 pathway target proteins, including the
cell cycle repressor CDKN1A and the apoptotic protein
TNFRSF10B (Figure 4F; Figure S5F) (Pappas et al., 2017). Our
analysis supports the possibility that the SCNA driver genes encoded on chromosome 1q inhibit p53 activity by repressing p53
pathway components or downstream target genes.
Discovery of a Potential Role for circRNAs in EMT
Regulation
Circular RNAs (circRNAs) have recently drawn interest for their
role in tumor biology (Chen et al., 2019; Dragomir and Calin,
2018; Hansen et al., 2013; Kristensen et al., 2018; Vo et al.,
2019). We identified 234 recurrent circRNAs (see Figure S6A
for the ten most commonly observed). The circRNA from the tumor-suppressor gene FBXW7 can be translated into a protein
product that can reduce the half-life of c-Myc (Yang et al.,
2018); two other circRNAs, circHIPK3 and circDOCK1, are
known to regulate cell growth and serve as cancer biomarkers
(Zhang et al., 2017b; Zheng et al., 2016). We observed an overall
positive correlation among circRNAs; such correlation was not
observed among their host genes (Figure 5A), suggesting coregulation of circRNAs at the global level. To identify possible
regulators, we correlated the protein levels of all RNA-binding
proteins (RBPs) with circRNA levels (Figure 5B; Table S5). The
protein level of QKI, a recently reported circRNA regulator
(Conn et al., 2015), was positively correlated with 35 circRNAs,
whereas the protein level of ESRP2 was negatively correlated
with 20 circRNAs. These RBPs might serve as master regulators

of circRNAs. QKI is upregulated during EMT and can promote
EMT by regulating hundreds of alternative splicing targets
(Conn et al., 2015; Nieto et al., 2016; Pillman et al., 2018). We
found a positive correlation between relative QKI protein level
and EMT score (Figure 5C; STAR Methods) and with the EMT activators ZEB1 and ZEB2 (Krebs et al., 2017; Zhang et al., 2015)
(Figures S6B and S6C). The level of ESRP2, which plays an
important role in maintaining epithelial features (Warzecha and
Carstens, 2012; Warzecha et al., 2009), was negatively correlated with QKI level, as previously reported (Conn et al., 2015;
Ishii et al., 2014; Mizutani et al., 2016) (Figure 5D).
Because miRNAs play critical roles in EMT (Zaravinos, 2015),
and circRNAs can serve as miRNA sponges to regulate miRNA
activity, we predicted miRNA binding sites in the 35 circRNAs
that were correlated with QKI level, finding potential binding sites
for 36 miRNAs (p < 0.02, Figure S6D; STAR Methods). We further
predicted sample-specific activities of these miRNAs based on
the level of their known mRNA targets (STAR Methods). We
found that the activities of these miRNAs were negatively correlated with QKI expression, although their abundances showed
varying relationships with QKI levels (Figure 5E). This suggests
that the activity of these miRNAs might be opposed by QKI,
possibly through QKI-mediated expression of circRNAs. Interestingly, we found known QKI regulators miR-200c and miR221 (Cochrane et al., 2009; Mukohyama et al., 2017; Pillman
et al., 2018) among the miRNAs with the strongest negative correlations between their activity and QKI levels; this set of miRNAs
also included miR-130a, miR-130b, and miR-183, which are predicted QKI regulators (Figures S6E–S6I) (Dweep et al., 2011;
Lewis et al., 2005). In summary, the observed positive correlation
between QKI and circRNAs, and the negative correlation of QKI
with the activity of specific miRNAs, suggests a mechanism promoting the EMT in EC (Figure 5F).
Proteomic Markers of Clinical and Genomic Tumor
Subtypes
We compared proteomic and transcriptomic changes between
subtypes (Table S6). Protein and mRNA changes were highly
correlated for all subtypes (Figures S7A–S7C). When comparing
MSI to MSS tumors, we confirmed that MLH1 and EPM2AIP1
were downregulated in MSI samples at both the protein and
mRNA levels (Figure 6A), likely due to methylation of their shared
promoter (Figure 4A), a common cause of microsatellite instability (Simpkins et al., 1999). However, PMS1 and PMS2, two
binding partners of MLH1, were downregulated only at the protein level (Figure 6A; Figure S7D). The stability of these proteins
is known to decrease in the absence of MLH1 (Chang et al.,
2000). We further identified upregulation of RPL22L1 in MSI

(C) 1q amplification is anticorrelated with p53 pathway activity. The samples are ranked based on their inferred p53 pathway activity. The triangles denote
recurrent TP53 mutations across multiple cancer types.
(D) Identifying novel p53 inhibitors encoded on 1q. On the top, all quantifiable genes in proteomics, transcriptomics, and copy number alterations are ranked
based on the correlation between the protein level and p53 activity. On the bottom, from top to bottom, 1q genes, 1q genes with SCNA cis effects, and 1q histone
modifiers with SCNA cis effects are highlighted.
(E) The correlation between SCNAs, mRNA level, and protein levels for 1q histone modifiers. Samples are ranked from lowest (left) to highest (right) copy number
values.
(F) SETDB1 protein levels showed anticorrelation with CDKN1A RNA.
See also Figure S5; Table S5.
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(A) Distributions of correlations between pairs of
circRNAs and between circRNAs and their host
genes.
(B) Numbers of circRNAs correlated to RBPs.
(C) Positive correlation is found between QKI protein level and EMT score.
(D) Negative correlation is found between QKI and
ESRP2 protein levels.
(E) Correlation between QKI protein level and
miRNA expression/activity.
(F) Schematic of our model shows QKI, circRNAs,
and miRNAs forming a positive feedback loop to
promote EMT in EC.
See also Figure S6; Table S5.
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DDR-high endometrioid tumors came
from the CNV-high, POLE, and MSI
genomic subgroups (Figure S7E), indicating that active DNA damage signaling
is largely independent of genomic
subtype.
tumors at both the mRNA and protein levels. Its paralog gene,
In order to nominate new chemotherapeutic targets for DDRRPL22, is mutated in many of the MSI tumors, and RPL22L1 pro- high tumors, we compared hyperphosphorylation, a proxy for
tein levels were highest in these tumors (Figure 6B, p = 0.002, abnormally high activity (Huang et al., 2017; Mertins et al.,
rank-sum test). MSI tumors could upregulate RPL22L1 to 2016; Mundt et al., 2018), between DDR-high and DDR-low tucompensate for the loss of RPL22; indeed, it has been shown mors, and found that several proteins that have known interacthat RPL22 and RPL22L1 share a synthetic lethal relationship tions with FDA-approved drugs were hyperphosphorylated in
DDR-high samples (Figure 6H). In particular, DNMT1 is a protein
(McDonald et al., 2017).
When comparing serous to endometrioid tumors, the most that was hyperphosphorylated in both endometrioid and serous
striking observation was that TP53BP1-S1763 and CHEK2- DDR-high tumors. This protein has several known inhibitors,
S163 were highly phosphorylated in serous tumors (Figure 6C). including azacitidine and decitabine (Hollenbach et al., 2010),
These sites are among those phosphorylated by PLK1 to inacti- that have demonstrated use in treating several myelodysplastic
vate the DNA damage response (DDR) and drive progression syndromes and other blood cancers. This finding highlights the
through the G2M checkpoint (van Vugt et al., 2010). The levels potential for personalized therapy beyond traditional PARP inof phosphorylated TP53BP1-S1763 and CHEK2-S163 were hibitors in tumors with elevated DNA damage.
correlated with PLK1 protein levels (Figures 6D and 6E),
The subset of endometrioid samples that are CNV-high have a
which correlated in turn with G2M checkpoint score (Figure 6F, prognosis that is similar to the more aggressive serous histotype
R = 0.67, p = 7.9e-14), indicating progression through the G2M (Kandoth et al., 2013). It is useful to determine whether they are
checkpoint. These results are consistent with previous studies also similar to serous tumors at a molecular level and therefore
showing that overexpression of PLK1 is a driver of chromosomal susceptible to the same treatments. It is also critical to determine
instability (de Cárcer et al., 2018) and that DDR and G2M check- what molecular underpinnings differentiate these tumors from
point activation are closely linked (Liu et al., 2000; Matsuoka et al., the more treatable endometrioid tumors in the other three
1998; Sancar et al., 2004; Wang et al., 2015). We generated a genomic subgroups, both in order to facilitate early diagnosis
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Figure 6. Proteomics-Driven Clinical Utility
(A) Differential levels of protein (green), phosphorylation sites (maroon), and acetylation sites (yellow) between MSI and MSS tumors.
(B) Comparison of RPL22L1 protein levels between MSI tumors with and without RPL22 indel and MSS tumors.
(C) Differential levels of protein (green), phosphorylation sites (maroon), and acetylation sites (yellow) between serous and endometrioid tumors.
(D–F) Correlation between PLK1 level and the levels of its substrates TP53BP1-S1763 (D) and CHEK2-S163 (E) and G2M checkpoint protein level (F).
(G) Dependence of PLK1 level on DNA damage signaling. * indicates p < 0.05
(H) Proteins with drug interactions that are enriched in DDR-high endometrioid and/or DDR-high serous samples (outlier analysis FDR < 0.05).
(I) Proteins with drug interactions that are enriched in serous or endometrioid CNV-high samples (outlier analysis FDR < 0.05).
See also Figure S7; Table S6.
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Figure 7. Immune Landscape of EC
(A) Putative neoantigens and CT antigens.
(B) Tumor samples are divided into four immune
subtypes by TMB and APM efficiency.
(C) Immune profiles of each immune subtype.
(D) Comparison of the JAK/STAT pathway between TMB-H/APM-H and TMB-H/APM-L groups.
* indicates p < 0.05; *** indicates p < 0.001.
See also Table S7.

C

D

and to pinpoint possible therapeutic targets. Although no proteins were differentially expressed between CNV-high endometrioid and non-CNV-high samples or between CNV-high serous
and non-CNV-high samples, a subset of proteins were differentially hyperphosphorylated; 45 proteins were hyperphosphorylated in both endometrioid and serous CNV-high samples,
whereas 479 proteins were hyperphosphorylated exclusively in
the serous comparison and 53 exclusively in the endometrioid
comparison (Figure S7I). Because patients with CNV-high tumors have a particularly poor prognosis regardless of histology,
we focused on identifying promising targets for future studies
developing new chemotherapy drugs by finding proteins that
are likely to be hyperactivated in CNV-high samples (Blumenberg et al., 2019). Of the proteins found in both comparisons,
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six have potentially useful known drug interactions; two of these, CDK12 and
SMARCA4, are targeted by FDAapproved drugs (Figure 6I). Of the proteins differentially phosphorylated only in
endometrioid CNV-high samples, six
additional proteins have known drug interactions, including one protein (PML)
that is the target of an FDA-approved antineoplastic drug (Figure 6I). As a specific
example, CDK12 is known to modulate
the susceptibility of ovarian cancer to
the PARP inhibitor olaparib (Bajrami
et al., 2014); the hyperphosphorylation of
CDK12 in EC suggests potential utility as
a target for sensitization of EC to PARP inhibitors. In addition, targeting of CDK12
has been shown to enhance responses
to immune checkpoint blockade (Omar
and Tolba, 2019), suggesting utility as an
adjunct to immunotherapy. Finally,
kinase activity inferred from phosphoproteomic data identified several kinases
activated in CNV-high endometrioid tumors compared to CNV-low tumors,
including CDK4, which can be targeted
by multiple FDA-approved drugs (Figure S7J; Table S6).
Tumor Antigens as Putative Vaccine
Antigens
Tumor antigens, including cancer/testis
(CT) antigens and neoantigens derived
from somatic mutations, can serve as candidates for vaccine
development in cancer immunotherapy (Almeida et al., 2009;
Lee et al., 2003). We found protein evidence for putative neoantigens in 49.3% of the samples. The POLE molecular subtype
contained the highest number of neoantigens per sample, followed by the MSI subtype (Figure 7A). Eight known CT antigens
were observed in R10% of tumors using a cutoff of R3-fold level
increase in tumor samples as compared with normal tissue (Figure 7A). Overall, 59% of tumors contained at least one CT antigen. Unlike neoantigen expression, CT antigen expression was
independent of POLE and MSI status. CT antigen IGF2BP3
was highly upregulated in serous tumors as compared with endometrioid; it has been identified as a biomarker of serous histology (Mhawech-Fauceglia et al., 2010; Zheng et al., 2008). We

also observed overexpression of ATAD2 or PBK CT antigens,
both of which have also been suggested as potential clinical biomarkers for EC (Berg et al., 2017; Krakstad et al., 2015). In addition to serving as cancer biomarkers, CT antigens are inherently
immunogenic. For example, peptides derived from IGF2BP3
have been shown to be immunogenic in vitro (Suda et al.,
2007) and in vivo in human esophageal cancer (Kono et al.,
2009). Overall, 78% of tumors had either evidence of a neoantigen or high expression of a common CT antigen (Figure 7A;
Table S7), demonstrating the utility of proteogenomics in identifying potential tumor antigens for vaccine development in cancer
immunotherapy.
Antigen Processing and Presentation Deficiency
Immune checkpoint inhibition is an increasingly successful cancer
immunotherapy. Higher tumor-mutation burden (TMB) has been
shown to predict clinical benefit of immune checkpoint inhibition
across human cancers (Samstein et al., 2019). However, effective
immune targeting of tumor cells also requires that the cellular antigen processing and presentation machinery (APM) effectively
displays the tumor antigens that allow T cells to recognize and
kill tumor cells (Baxevanis et al., 2019; Eggermont et al., 2014).
We found high variation in APM efficiency (estimated based on
APM protein levels, see STAR Methods) that was independent
of TMB (Figure 7B). We divided the tumors into four groups based
on TMB and APM scores (STAR Methods). We then quantified the
immune-cell infiltration scores of each tumor with single sample
gene-set enrichment analysis based on recently published immune-cell signatures (STAR Methods; Table S7) (Charoentong
et al., 2017). Cell-type immune scores (p < 0.05, one-way
ANOVA) are shown in Figure 7C. Consistent with the inference
above, the TMB-high and APM-low (TMB-H/APM-L) group had
a relatively lower immune score for most of the immune cells
than the TMB-high and APM-high (TMB-H/APM-H) group,
including cytotoxic CD8+ T cells. Interestingly, TMB-low and
APM-high (TMB-L/APM-H) had the highest immune score despite
its low TMB. However, the high score appears to be dependent on
high levels of suppressive immune cells, including myeloidderived suppressor cells and regulatory T cells (Bianchi et al.,
2011; Wang et al., 2017); this group had lower infiltration of activated CD8+ and CD4+ T cells than did TMB-H/APM-H, which is
suggestive of an immunosuppressive microenvironment. These
results indicate that TMB and APM act independently to shape
the tumor immune microenvironment in EC and could independently recruit different populations of immune cells.
Although recent studies have shown TMB to be an independent predictor of response to immunotherapy (Goodman et al.,
2017; Samstein et al., 2019), our results showed that high-TMB
tumors have diverse APM efficiency and immune microenvironments. Based on the prevalence of microsatellite indel-derived
JAK1 mutations in MSI EC samples (Figure 1) and a correlation
between the presence of microsatellite indel-derived JAK1 mutations and higher tumor grade in both this and the TCGA cohort
(Figure S2C), we focused our analysis on the JAK/STAT
pathway, which activates interferon (IFN) pathways to regulate
antigen presentation (Aaronson and Horvath, 2002; Schindler
et al., 2007). We observed that the TMB-H/APM-L group had
lower IFNg and IFNa activity than the TMB-H/APM-H group (Fig-

ure 7C). The two POLE samples in the TMB-H/APM-L group had
truncation mutations in JAK1 and STAT1, respectively (Figure 7D); we also found enrichment of JAK1 truncation mutations
in the TMB-H/APM-L group. Because most of the JAK1 truncation mutations in MSI tumors are derived from microsatellite
indels, which are much more common in EC than in the MSI
subtype of colon cancer (Kim et al., 2013) (Figure S2B), JAK1 microsatellite indels could represent a major immune evasion
mechanism in MSI EC, a theory which has also been considered
in other cancer types (Shin et al., 2017; Stelloo et al., 2016).
TMB-H/APM-L tumors without JAK1/STAT1 mutations had
lower protein levels of antigen peptide transporters including
TAP1, TAP2, and TAP2BP, providing an alternative mechanism
for repressing antigen presentation and suppressing anti-tumor
immune response (Harel et al., 2019). Moreover, HLA protein
levels were lower in TMB-H/APM-L tumors than in TMB-H/
APM-H tumors. In summary, these results suggest several
possible mechanisms by which EC cells could suppress the
APM, leading to immune evasion. Although the FDA has
approved MSI as a marker of immunotherapy for solid tumors
(Lemery et al., 2017), our results suggest that JAK1/STAT1 mutations and TAP levels, which are markers of APM deficiency,
should also be taken into account when selecting EC patients
for treatment with immune checkpoint inhibitors.
DISCUSSION
This study provides a comprehensive overview of the molecular
systems of EC at the genomic, transcriptomic, and proteomic
levels. We confirmed protein-level expression of predicted events
previously described at the genomic and transcriptomic level.
Beyond that, we clearly demonstrated that distinct EC subtypes
can be reliably distinguished by their patterns of protein levels
and subsequent post-translational modifications. Although it is
currently unclear how the distinct genomic subtypes defined by
TCGA can best be leveraged to improve outcomes for women
diagnosed with EC, the functional information provided by proteomic measurements, including protein phosphorylation and acetylation, provides a basis for a deeper understanding of EC biology
and new approaches to clinical management.
A perennial issue has been the identification of the subset of
low-grade, low-stage EC with paradoxically poor outcomes.
Constitutive b-catenin activation through CTNNB1 mutations
and other mechanisms has previously been associated with
less favorable outcomes in low-grade, low-stage endometrioid
EC (Liu et al., 2014). In this paper, we identify collaborating
mechanisms of pathway activation arising when the known effects of CTNNB1 somatic mutations are coupled with APC mutations. These findings could help refine which tumors will
behave in a more aggressive manner than expected and expand
the range of biomarkers used for adjuvant therapies.
The consequences of various common TP53 mutations are
thought to affect treatment outcomes (Meng et al., 2018); here
we describe the effect of gain-of-function TP53 mutations on
the Aurora kinase pathway, supporting reported associations
between AURKA expression and poor outcomes in EC (Umene
et al., 2015) and providing a theoretical basis for the use of
AURKA inhibitors in these tumors. On a related note, 1q
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amplification has been associated with poor outcomes in seemingly favorable endometrioid EC (Depreeuw et al., 2017). These
observations could be used to stratify treatment for more
aggressive EC tumors.
EMT is an important component of EC progression with prognostic implications (Tanaka et al., 2013). In this study we uncovered evidence for a novel regulatory pathway involving QKI,
circRNA, and ESRP2. ESRP2 regulates alternative splicing
events associated with epithelial phenotypes of cells (Ishii
et al., 2014) and plays a critical role during EMT by regulating isoforms of FGFR2, CD44, CTNND1, and ENAH (Lamouille et al.,
2014; Warzecha et al., 2009). Through its known function in isoform regulation, ESRP2 could also directly regulate circRNA
levels, and, if so, it could compete with QKI in circRNA-mediated
gene regulation. Further work is needed to investigate the interplay of ESRP2 with circRNAs in EMT.
High-grade endometrioid and serous EC are associated with
frequent recurrences and poor clinical outcomes even when
diagnosed at early stages; unfortunately, consistently effective
therapeutic options for these cancers are limited. We have identified multiple gene products that are highly expressed in the
CNV-high subset of ECs that includes all serous EC and many
of the high-grade ECs profiled. One of these gene products,
CDK12, can be targeted to enhance clinical responses to immune checkpoint blockade (Omar and Tolba, 2019), providing
an opportunity for improved selection of EC patients for checkpoint blockade immunotherapy. Long-term, these observations
posit multiple strategies potentially useful for clinically managing
CNV-high and other EC subtypes. It will be important to determine whether the distinguishing features we have observed are
associated with distinct rates of tumor recurrence, response to
therapy, and clinical outcomes as the demographic data available for this prospective cohort continues to mature.
Although immunotherapy approaches, including checkpoint
inhibition and tumor vaccination, have been highly successful
as cancer treatments, a significant proportion of patients fail to
respond to these therapies. Our results indicate that measuring
the capability of the tumor to process and present antigens
would provide additional and possibly more effective criteria
for the selection of patients for immunotherapy beyond the simple measurement of tumor mutation burden.
Integrating comprehensive quantitative measurements of protein, phosphorylation, and acetylation with genomic and transcriptomic measurements not only has provided novel insights
into fundamental biological processes associated with carcinogenesis but also has provided intriguing leads for new therapeutic approaches in EC, including potential criteria for selecting the
most appropriate therapies. Although the results presented
herein are predominantly observational, they provide the basis
for multiple hypotheses of clinical relevance that can and should
be further explored by the scientific community.
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Thermo Scientific

Catalog: 20291

Ethylenediaminetetraacetic acid

Sigma

Catalog: E7889

Formic acid

Sigma

Catalog: 33015

Iodoacetamide

Thermo Scientific

Catalog: A3221

Leupeptin

Roche

Catalog: 11017101001

Lysyl Endopeptidase

Wako Chemicals

Catalog 129-02541

Phenylmethylsulfonyl fluoride

Sigma

Catalog: 93482

Phosphatase Inhibitor Cocktail 2

Sigma

Catalog: P5726

Phosphatase Inhibitor Cocktail 3

Sigma

Catalog: P0044

Reversed-phase tC18 SepPak

Waters

Catalog: WAT054925

Sequencing grade modified trypsin

Promega

Catalog: V517

Sodium chloride

Sigma

Catalog: S7653

Sodium fluoride

Sigma

Catalog: S7920

Tandem mass tags - 10plex

Thermo Scientific

Catalog: 90110

Urea

Sigma

Catalog: U0631

Ascore (v1.0.6858)

Beausoleil et al., 2006

https://github.com/PNNL-Comp-Mass-Spec/
AScore/releases

BlackSheep

Blumenberg et al., 2019

https://github.com/ruggleslab/blackSheep

Bowtie2 (v2.3.3)

Langmead and Salzberg,
2012

http://bowtie-bio.sourceforge.net/bowtie2/index.shtml

BWA (v0.7.17-r1188)

Li and Durbin, 2010

http://bio-bwa.sourceforge.net/

CIRI (v2.0.6)

Gao et al., 2015

https://sourceforge.net/projects/ciri/

cptac (Python package)

In preparation

https://pypi.org/project/cptac/

eriscript (v0.5.5)

Benelli et al., 2012

https://sites.google.com/site/bioericscript/

GSVA (v1.30.0)

Hänzelmann et al., 2013

https://bioconductor.org/packages/release/
bioc/html/GSVA.html

HotSpot3D (v1.8.2)

Niu et al., 2016

https://github.com/ding-lab/hotspot3d

INTEGRATE v(0.2.6)

Zhang et al., 2016b

https://sourceforge.net/p/integrate-fusion/
wiki/Home/

LinkedOmics

Vasaikar et al., 2018

http://www.linkedomics.org

MASIC

Monroe et al., 2008

https://github.com/PNNL-Comp-Mass-Spec/
MASIC/releases

Software and Algorithms

(Continued on next page)
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Continued
REAGENT or RESOURCE

SOURCE

IDENTIFIER

metaX

Wen et al., 2017

https://github.com/wenbostar/metaX

MS-GF+

Kim and Pevzner, 2014

https://github.com/MSGFPlus/msgfplus/releases

MSIsensor (v0.2)

Niu et al., 2014

https://github.com/ding-lab/msisensor

MSMuTect (v1.0)

Maruvka et al., 2017

https://www.nature.com/articles/nbt.3966#supplementaryinformation

MuSiC (v0.4)

Dees et al., 2012

http://gmt.genome.wustl.edu/packages/genome-music/
index.html

Mutect (v2)

Cibulskis et al., 2013

https://software.broadinstitute.org/cancer/cga/mutect

mzRefinery

Gibbons et al., 2015

https://omics.pnl.gov/software/mzrefinery

NeoFlow

In-house

https://github.com/bzhanglab/neoflow

Optitype

Szolek et al., 2014

http://github.com/FRED-2/OptiType

PDV

Li et al., 2019

http://pdv.zhang-lab.org/

Pepcentric

In preparation

http://pepcentric.arsci.com:8080/

PepQuery

Wen et al., 2019

http://pepquery.org

Pindel (v0.2.5)

Ye et al., 2009

http://gmt.genome.wustl.edu/packages/pindel/

PROGENy

Schubert et al., 2018

https://bioconductor.org/packages/release/bioc/
html/progeny.html

PTMcosmos

(In preparation)

https://ptmcosmos.wustl.edu/

pyQUILTS (v1.0)

Ruggles et al., 2016

http://quilts.fenyolab.org

RNA22 (v2)

Miranda et al., 2006

https://cm.jefferson.edu/rna22/Interactive/

RSEM (v1.3.1)

Li and Dewey, 2011

https://deweylab.github.io/RSEM/

SignatureAnalyzer (v0421-2017)

Tan and Févotte, 2013

https://software.broadinstitute.org/cancer/cga/msp

STAR-Fusion (v1.6.0)

Haas et al., 2017

https://github.com/STAR-Fusion/STAR-Fusion/wiki

Strelka (v2)

Saunders et al., 2012

https://github.com/Illumina/strelka

Trimmomatic (v0.38)

Bolger et al., 2014

http://www.usadellab.org/cms/?page=trimmomatic

Varscan (v2.3.8)

Koboldt et al., 2012

http://varscan.sourceforge.net/

XGboost (v0.81)

Chen and Guestrin, 2016

https://xgboost.readthedocs.io/en/latest/

CPTAC Data Portal

Edwards et al., 2015

https://cptac-data-portal.georgetown.edu/cptacPublic

CTdatabase

Chen et al., 1997

http://www.cta.lncc.br

dbGaP

Tryka et al., 2014

https://www.ncbi.nlm.nih.gov/gap/

Genomic Data Commons

Grossman et al., 2016

https://gdc.cancer.gov

Mirtarbase (v7.0)

Hsu et al., 2011

http://mirtarbase.mbc.nctu.edu.tw/php/index.php

RefSeq (downloaded from UCSC
Genome Browser 2018/06/29)

O’Leary et al., 2016

https://www.ncbi.nlm.nih.gov/refseq/; https://
genome.ucsc.edu/cgi-bin/hgTables; RRID: SCR_003496

UniProt (r2017.06, r2019.01)

UniProt Consortium, 2019

https://www.uniprot.org/; RRID: SCR_002380

Other

LEAD CONTACT AND MATERIALS AVAILABILITY
Further information and requests for resources should be directed to the Lead Contact, David Fenyö (david@fenyolab.org). This study
did not generate new unique reagents.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Patient Selection
The tumor, normal tissue, and whole blood samples used in this manuscript were prospectively collected between April 2016 and
May 2017 for the CPTAC project. There are three types of normals were included in our analysis which are adjacent normal tissue
without specific enrichment (adjacent normal), enriched endometrium normal (enriched normal), and adjacent normal without endometrium (myometrium normal). Biospecimens were collected from newly diagnosed patients with endometrial cancer (EC) who were
undergoing surgical resection and had received no prior treatment for their disease, including chemotherapy or radiotherapy, and
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were collected independent of grade or stage. EC cases were graded using the FIGO (International Federation of Gynecology and
Obstetrics) system or the American Joint Committee on Cancer TNM staging system, which are functionally identical.
METHOD DETAILS
Sample Collection
The CPTAC Biospecimen Core Resource (BCR) at the Pathology and Biorepository Core of the Van Andel Research Institute in Grand
Rapids, Michigan manufactured and distributed biospecimen kits to the Tissue Source Sites (TSS) located in the US, Europe, and
Asia. Each kit contained a set of pre-manufactured labels for unique tracking of every specimen respective to TSS location, disease,
and sample type, used to track the specimens through the BCR to the CPTAC proteomic and genomic characterization centers.
Tissue specimens averaging 250 mg were snap-frozen by the TSS within a 30 min cold ischemic time (CIT) (CIT average = 18 min)
and an adjacent segment was formalin-fixed paraffin-embedded (FFPE) and H&E stained by the TSS for quality assessment to meet
the CPTAC EC requirements. Routinely, several tissue segments for each case were collected. Tissues were flash frozen in liquid
nitrogen (LN2) then transferred to a liquid nitrogen freezer for storage until approval for shipment to the BCR.
Specimens were shipped using a cryoport that maintained an average temperature of under 140 C to the BCR with a time and
temperature tracker to monitor the shipment. Receipt of specimens at the BCR included a physical inspection and review of the time
and temperature tracker data for specimen integrity, followed by barcode entry into a biospecimen tracking database. Specimens
were again placed in storage at LN2 temperatures until further processing. Acceptable EC tumor tissue segments were determined
by TSS pathologists based on the percent viable tumor nuclei (> 80%), total cellularity (> 50%), and necrosis (< 20%). Segments
received at the BCR were verified by BCR and Leidos Biomedical Research (LBR) pathologists and the percent of total area of tumor
in the segment was also documented. Additionally, disease-specific working group pathology experts reviewed the morphology to
clarify or standardize specific disease classifications and correlation to the proteomic and genomic data.
Specimens selected for the discovery set were determined on the maximal percent in the pathology criteria and best weight. Specimens were pulled from the biorepository using an LN2 cryocart to maintain specimen integrity and then cryopulverized. The
cryopulverized specimen was divided into aliquots for DNA (30mg) and RNA (30mg) isolation and proteomics (50mg) for molecular
characterization. Nucleic acids were isolated and stored at 80 C until further processing and distribution; cryopulverized protein
material was returned to the LN2 freezer until distribution. Shipment of the cryopulverized segments used cryoports for distribution
to the proteomic characterization centers and shipment of the nucleic acids used dry ice shippers for distribution to the genomic
characterization centers; a shipment manifest accompanied all distributions for the receipt and integrity inspection of the specimens
at the destination. The DNA sequencing was performed at the Broad Institute, Cambridge, MA and RNA sequencing was performed
at the University of North Carolina, Chapel Hill, NC. Material for proteomic analyses was sent to the Proteomic Characterization Center (PCC) at Pacific Northwest National Laboratory (PNNL), Richland, Washington.
Sample Processing for Genomic DNA and Total RNA Extraction
Our study sampled a single site of the primary tumor from surgical resections, due to the internal requirement to process a minimum
of 125mg of tumor issue and 50mg of adjacent normal tissue. DNA and RNA were extracted from tumor and adjacent normal specimens in a co-isolation protocol using QIAGEN’s QIAsymphony DNA Mini Kit and QIAsymphony RNA Kit. Genomic DNA was also
isolated from peripheral blood (3-5mL) to serve as matched normal reference material. The Qubit dsDNA BR Assay Kit was used
with the Qubit 2.0 Fluorometer to determine the concentration of dsDNA in an aqueous solution. Any sample that passed quality
control and produced enough DNA yield to go through various genomic assays was sent for genomic characterization. RNA
quality was quantified using both the NanoDrop 8000 and quality assessed using Agilent Bioanalyzer. A sample that passed RNA
quality control and had a minimum RIN (RNA integrity number) score of 7 was subjected to RNA sequencing. Identity match for germline, normal adjacent tissue, and tumor tissue was assayed at the BCR using the Illumina Infinium QC array. This beadchip contains
15,949 markers designed to prioritize sample tracking, quality control, and stratification. The genomic DNA and total RNA extraction
were only applied to a subset of adjacent normal tissues without enrichment for endometrium.
Whole Exome Sequencing
Library Construction
Library construction was performed as described in (Fisher et al., 2011), with the following modifications: initial genomic DNA input
into shearing was reduced from 3mg to 20-250ng in 50mL of solution. For adaptor ligation, Illumina paired-end adapters were replaced
with palindromic forked adapters, purchased from Integrated DNA Technologies, with unique dual-indexed molecular barcode sequences to facilitate downstream pooling. Kapa HyperPrep reagents in 96-reaction kit format were used for end repair/A-tailing,
adaptor ligation, and library enrichment PCR. In addition, during the post-enrichment SPRI cleanup, elution volume was reduced
to 30mL to maximize library concentration, and a vortexing step was added to maximize the amount of template eluted.
In-solution Hybrid Selection
After library construction, libraries were pooled into groups of up to 96 samples. Hybridization and capture were performed using the
relevant components of Illumina’s Nextera Exome Kit and following the manufacturer’s suggested protocol, with the following exceptions.First, all libraries within a library construction plate were pooled prior to hybridization. Second, the Midi plate from Illumina’s
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Nextera Exome Kit was replaced with a skirted PCR plate to facilitate automation. All hybridization and capture steps were automated
on the Agilent Bravo liquid handling system.
Preparation of Libraries for Cluster Amplification and Sequencing
After post-capture enrichment, library pools were quantified using qPCR (automated assay on the Agilent Bravo) using a kit purchased from KAPA Biosystems with probes specific to the ends of the adapters. Based on qPCR quantification, libraries were
normalized to 2nM.
Cluster Amplification and Sequencing
Cluster amplification of DNA libraries was performed according to the manufacturer’s protocol (Illumina) using exclusion amplification chemistry and flowcells. Flowcells were sequenced utilizing sequencing-by-synthesis chemistry. The flowcells were then
analyzed using RTA v.2.7.3 or later. Each pool of whole exome libraries was sequenced on paired 76 cycle runs with two 8 cycle index
reads across the number of lanes needed to meet coverage for all libraries in the pool. Pooled libraries were run on HiSeq4000 pairedend runs to achieve a minimum of 150x on target coverage per each sample library. The raw Illumina sequence data were demultiplexed and converted to fastq files; adaptor and low-quality sequences were trimmed. The raw reads were mapped to the hg38
human reference genome and the validated bams were used for downstream analysis and variant calling.
PCR-Free Whole Genome Sequencing
Preparation of Libraries for Cluster Amplification and Sequencing
An aliquot of genomic DNA (350ng in 50mL) was used as the input into DNA fragmentation (aka shearing). Shearing was performed
acoustically using a Covaris focused-ultrasonicator, targeting 385bp fragments. Following fragmentation, additional size selection
was performed using a SPRI cleanup. Library preparation was performed using a commercially available kit provided by KAPA Biosystems (KAPA Hyper Prep without amplification module) and with palindromic forked adapters with unique 8-base index sequences
embedded within the adaptor (purchased from IDT). Following sample preparation, libraries were quantified using quantitative PCR
(kit purchased from KAPA Biosystems), with probes specific to the ends of the adapters. This assay was automated using Agilent’s
Bravo liquid handling platform. Based on qPCR quantification, libraries were normalized to 1.7nM and pooled into 24-plexes.
Cluster Amplification and Sequencing (HiSeq X)
Sample pools were combined with HiSeqX Cluster Amp Reagents EPX1, EPX2, and EPX3 into single wells on a strip tube using the
Hamilton Starlet Liquid Handling system. Cluster amplification of the templates was performed according to the manufacturer’s protocol (Illumina) with the Illumina cBot. Flowcells were sequenced to a minimum of 15x on HiSeqX utilizing sequencing-by-synthesis
kits to produce 151bp paired-end reads. Output from Illumina software was processed by the Picard data processing pipeline to yield
BAM files containing demultiplexed, aggregated, aligned reads. All sample information tracking was performed by automated LIMS
messaging.
Illumina Infinium MethylationEPIC BeadChip Array
The MethylationEPIC array uses an 8-sample version of the Illumina Beadchip capturing > 850,000 methylation sites per sample.
250ng of DNA was used for the bisulfite conversation using Infinium MethylationEPIC BeadChip Kit. The EPIC array includes sample
plating, bisulfite conversion, and methylation array processing. After scanning, the data was processed through an automated genotype calling pipeline. Data generated consisted of raw idats and a sample sheet.
RNA Sequencing
QA and QC of RNA Analytes
All RNA analytes were assayed for RNA integrity, concentration, and fragment size. Samples for total RNA-seq were quantified on a
TapeStation system (Agilent, Inc. Santa Clara, CA). Samples with RINs > 8.0 were considered high quality.
Total RNA-seq Library Construction
Total RNA Libraries were prepared on an Agilent Bravo Automated Liquid Handling System. Quality control was performed at every
step, and the libraries were quantified using a TapeStation system.
Total RNA Sequencing
Indexed libraries were prepared and run on HiSeq4000 paired-end 75 base pairs to generate a minimum of 120 million reads per
sample library with a target of greater than 90% mapped reads. The raw Illumina sequence data were demultiplexed and converted
to fastq files, and adaptor and low-quality sequences were quantified. Samples were then assessed for quality by mapping reads to
hg38, estimating the total number of mapped reads, amount of RNA mapping to coding regions, amount of rRNA in sample, number
of genes expressed, and relative expression of housekeeping genes. Samples passing this QA/QC were then clustered with other
expression data from similar and distinct tumor types to confirm expected expression patterns. Atypical samples were then SNP
typed from the RNA data to confirm source analyte. FASTQ files of all reads were then uploaded to the GDC repository.
miRNA-seq Library Construction
miRNA-seq library construction was performed from the RNA samples using the NEXTflex Small RNA-Seq Kit (v3, PerkinElmer, Waltham, MA) and barcoded with individual tags following the manufacturer’s instructions. Libraries were prepared on Sciclone Liquid
Handling Workstation. Quality control was performed at every step, and the libraries were quantified using a TapeStation system and
an Agilent Bioanalyzer using the Small RNA analysis kit. Pooled libraries were then size selected according to NEXTflex Kit specifications using a Pippin Prep system (Sage Science, Beverly, MA).
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miRNA Sequencing
Indexed libraries were loaded on the HiSeq4000 to generate a minimum of 10 million reads per library with a minimum of 90% reads
mapped. The raw Illumina sequence data were demultiplexed and converted to FASTQ files for downstream analysis. Resultant data
were analyzed using a variant of the small RNA quantification pipeline developed for TCGA (Chu et al., 2016). Samples were assessed
for the number of miRNAs called, species diversity, and total abundance. Samples were uploaded to the GDC repository.
MS Sample Processing and Data Collection
Protein Extraction and Lys-C/Trypsin Tandem Digestion
The cryopulverized tumor and normal uterine tissue samples were obtained through the CPTAC Biospecimen Core Resource.
Approximately 50 mg of each of the pulverized uterine tumor and normal tissues were homogenized separately in 200 mL of lysis
buffer (8 M urea, 75 mM NaCl, 50 mM Tris, pH 8.0, 1 mM EDTA, 2 mg/mL aprotinin, 10 mg/mL leupeptin, 1 mM PMSF, 10 mM
NaF, 1:100 v/v Sigma phosphatase inhibitor cocktail 2, 1:100 v/v Sigma phosphatase inhibitor cocktail 3, 20 mM PUGNAc, and
5 mM sodium butyrate). Lysates were precleared by centrifugation at 20,000 g for 10 min at 4 C and protein concentrations were
determined by BCA assay (ThermoFisher Scientific) and adjusted to 8 mg/mL with lysis buffer. Proteins were reduced with 5 mM dithiothreitol for 1 h at 37 C and subsequently alkylated with 10 mM iodoacetamide for 45 min at 25 C in the dark. Samples were diluted
1:3 with 50 mM Tris, pH 8.0 and digested with Lys-C (Wako) at 1:50 enzyme-to-substrate ratio. After 2 h of digestion at 25 C, an
aliquot of the same amount of sequencing-grade modified trypsin (Promega, V5117) was added to the samples and further incubated
at 25 C for 14 h. The digested samples were then acidified with 100% formic acid to 1% of the final concentration of formic acid and
centrifuged for 15 min at 1,500 g at 4 C before transferring samples into new tubes leaving resulted pellet behind. Tryptic peptides
were desalted on C18 SPE (Waters tC18 SepPak, WAT054925) and dried using Speed-Vac.
TMT-10 Labeling of Peptides
Desalted peptides from each sample were labeled with 10-plex TMT reagents according to the manufacturer’s instructions
(ThermoFisher Scientific). Peptides (400 mg) from each of the tumors were dissolved in 400 mL of 50 mM HEPES, pH 8.5 solution,
and mixed with 3.2 mg of TMT reagent that was dissolved freshly in 164 mL of anhydrous acetonitrile. Channel 126 was used for labeling the internal reference sample (pooled from all tumor and normal samples) throughout the sample analysis. After 1 h incubation
at RT, 32 mL of 5% hydroxylamine was added and incubated for 15 min at RT to quench the reaction. Peptides labeled by different
TMT reagents were then mixed, dried using Speed-Vac, reconstituted with 3% acetonitrile, 0.1% formic acid and desalted on tC18
SepPak SPE columns.
Peptide Fractionation by Basic Reversed-Phase Liquid Chromatography (bRPLC)
Approximately 3.5 mg of 10-plex TMT labeled sample was separated on a reversed phase Agilent Zorbax 300 Extend-C18 column
(250 mm 3 4.6 mm column containing 3.5-mm particles) using the Agilent 1200 HPLC System. Solvent A was 4.5 mM ammonium
formate, pH 10, 2% acetonitrile and solvent B was 4.5 mM ammonium formate, pH 10, 90% acetonitrile. The flow rate was 1 mL/min
and the injection volume was 900 mL. The LC gradient started with a linear increase of solvent B to 16% in 6 min, then linearly
increased to 40% B in 60 min, 4 min to 44% B, 5 min to 60% B and another 14 of 60% solvent B. A total of 96 fractions were collected
into a 96 well plate throughout the LC gradient. These fractions were concatenated into 24 fractions by combining 4 fractions that are
24 fractions apart (i.e., combining fractions #1, #25, #49, and #73; #2, #26, #50, and #74; and so on). For proteome analysis, 5% of
each concatenated fraction was dried down and re-suspended in 2% acetonitrile, 0.1% formic acid to a peptide concentration of
0.1 mg/mL for LC-MS/MS analysis. The rest of the fractions (95%) were further concatenated into 12 fractions (i.e., by combining
fractions #1 and #13; #3 and #15; and so on), dried down, and subjected to immobilized metal affinity chromatography (IMAC) for
phosphopeptide enrichment.
Phosphopeptide Enrichment Using IMAC
Fe3+-NTA-agarose beads were freshly prepared using the Ni-NTA Superflow agarose beads (QIAGEN, #30410) for phosphopeptide
enrichment. For each of the 12 fractions, peptides were reconstituted in 500 mL IMAC binding/wash buffer (80% acetonitrile, 0.1%
trifluoroacetic acid) and incubated with 20 mL of the 50% bead suspension for 30 min at RT. After incubation, the beads were sequentially washed with 50 mL of wash buffer (1X), 50 mL of 50% acetonitrile, 0.1% trifluoroacetic acid (1X), 50 mL of wash buffer (1X), and
50 mL of 1% formic acid (1X) on the stage tip packed with 2 discs of Empore C18 material (Empore Octadecyl C18, 47 mm; Supleco,
66883-U). Phosphopeptides were eluted from the beads on C18 using 70 mL of elution buffer (500 mM K2HPO4, pH 7.0). Sixty microliter of 50% acetonitrile, 0.1% formic acid was used for elution of phosphopeptides from the C18 stage tips after two washes with
100 mL of 1% formic acid. Samples were dried using Speed-Vac and later reconstituted with 10 mL of 3% acetonitrile, 0.1% formic
acid for LC-MS/MS analysis.
Immunoaffinity Purification of Acetylated Peptides
Tryptic peptides from the flow-through of IMAC were combined into four samples follow concatenation scheme and dried down
using Speed-Vac. The dried peptides were reconstituted in 1.4 mL of the immunoaffinity purification (IAP) buffer (50 mM
MOPS/NaOH pH 7.2, 10 mM Na2HPO4 and 50 mM NaCl). After dissolving the peptide, the pH of the peptide solution was checked
using pH indicator paper. The amount of reconstituted peptides was quantified via BCA assay and concatenated into 4 fractions by
combining 3 fractions that were 4 fractions apart (i.e., combining fractions #1, #5 and #9 as a new fraction). The antibody beads from
PTMScan Acetyl-Lysine Motif [Ac-K] Kit (Cell Signaling, #13416) were freshly prepared. Briefly, the antibody beads were centrifuged at 2,000 x g for 30 s and all buffer from the beads were removed; the antibody beads were then washed with 1 mL of IAP buffer
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for four times and finally resuspend in 40 mL of IAP buffer. For each fraction, half of the antibody in each tube was transferred to the
peptide solution and incubated on a rotator overnight at 4 C. After removing the supernatant, the reacted beads were washed with
1mL of PBS buffer five times. For the elution of acetylated peptides, the antibody beads were incubated 2 times each with 50 mL of
0.15% TFA at room temperature for 10 min. The eluted peptides were transferred to the stage tip packed with two discs of Empore
C18 material. The C18 stage tips were washed by 1% formic acid and 50% acetonitrile, and 0.1% formic acid was used for elution of
peptides from the C18 stage tips. The eluted peptides were dried using Speed-Vac, and reconstituted with 13 mL of 3% acetonitrile,
0.1% formic acid right before the LC-MS/MS analysis.
The acetylated peptides prepared by IP from the IMAC flow-through may very well miss those peptides that are both phosphorylated and acetylated. Splitting the samples for independent IP and IMAC may improve the chance of recovering such peptides,
assuming having both PTMs on the same peptide does not impact the affinity of either the IP or IMAC process. However, acetylated
peptides are estimated to be 10 times lower in abundance than the phosphopeptides, hence much larger input may be needed to
recover the dual-modified peptides. Given the extremely low stoichiometry of these dual-modified peptides and the sample size limitations, it was not pursued in this work.
LC-MS/MS Analysis
Fractionated samples prepared for global proteome, phosphoproteome, and acetylome analysis were separated using a
nanoACQUITY UPLC system (Waters) by reversed-phase HPLC. The analytical column was manufactured in-house using
ReproSil-Pur 120 C18-AQ 1.9 mm stationary phase (Dr. Maisch GmbH) and slurry packed into a 25-cm length of 360 mm o.d. x
75 mm i.d. fused silica picofrit capillary tubing (New Objective). The analytical column was heated to 50 C using an AgileSLEEVE column heater (Analytical Sales and Services). The analytical column was equilibrated to 98% Mobile Phase A (MP A, 0.1% formic acid/
3% acetonitrile) and 2% Mobile Phase B (MP B, 0.1% formic acid/90% acetonitrile) and maintained at a constant column flow of
200 nL/min. The sample was injected into a 5 mL loop placed in-line with the analytical column which initiated the gradient profile
(min:%MP B): 0:2, 1:6, 85:30, 94:60, 95:90, 100:90, 101:50, 110:50. The column was allowed to equilibrate at start conditions for
30 min between analytical runs.
MS analysis was performed using an Orbitrap Fusion Lumos mass spectrometer (ThermoFisher Scientific). The global proteome
and phosphoproteome samples were analyzed under identical conditions. Electrospray voltage (1.8 kV) was applied at a carbon
composite union (Valco Instruments) coupling a 360 mm o.d. x 20 mm i.d. fused silica extension from the LC gradient pump to the
analytical column and the ion transfer tube was set at 250 C. Following a 25-min delay from the time of sample injection, Orbitrap
precursor spectra (AGC 4x105) were collected from 350-1800 m/z for 110 min at a resolution of 60K along with data dependent Orbitrap HCD MS/MS spectra (centroid) at a resolution of 50K (AGC 1x105) and max ion time of 105 ms for a total duty cycle of 2 s. Masses
selected for MS/MS were isolated (quadrupole) at a width of 0.7 m/z and fragmented using a collision energy of 30%. Peptide mode
was selected for monoisotopic precursor scan and charge state screening was enabled to reject unassigned 1+, 7+, 8+, and > 8+
ions with a dynamic exclusion time of 45 s to discriminate against previously analyzed ions between ± 10 ppm. The acetylome samples were analyzed under similar conditions except that the max ion time was 200 ms.
Construction and Utilization of the Comparative Reference Samples
As a quality control measure, two ‘‘Comparative Reference’’ (‘‘CompRef’’) samples were generated as previously described (Li et al.,
2013; Tabb et al., 2016) and used to monitor the longitudinal performance of the proteomics workflow throughout the course of this
study. Briefly, patient-derived xenograft (PDX) tumors from established basal and luminal breast cancer intrinsic subtypes were
raised subcutaneously in 8-week old NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ mice (Jackson Laboratories, Bar Harbor, ME) using procedures reviewed and approved by the Institutional Animal Care and Use Committee at Washington University in St. Louis. Xenografts
were grown in multiple mice, pooled, and cryopulverized to provide a sufficient amount of uniform material for the duration of the
study. Full proteome, phosphoproteome and acetylome process replicates of each of the two CompRef samples were prepared
and analyzed as standalone 10-plex TMT experiments alongside every 4 TMT-10 experiments of the study samples, using the
same analysis protocol as the patient samples. These interstitially analyzed CompRef samples were evaluated for depth of proteome,
phosphoproteome, and acetylome coverage and for consistency in quantitative comparison between the basal and luminal models.
QUANTIFICATION AND STATISTICAL ANALYSIS
Tumor Exclusion Criteria
In the PCA analysis of proteomics (Figures 1D and 1E) and RNA-Seq data, three tumor samples were grouped with normal tissues.
We estimated tumor purity using a methylation-based deconvolution method (Onuchic et al., 2016). The three samples were found to
have tumor purity < 10% and were excluded from downstream analysis. Six more samples were excluded for other reasons,
including four from histologic types where there were too few tumors for meaningful statistical analysis (three carcinosarcoma
and one clear cell), one which was not treatment-naive, and one which was a tumor that was analyzed twice (the lower quality replicate was excluded).
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Genomic Data Analysis
Copy Number Calling
Copy number variation was detected using BIC-seq2 (Xi et al., 2016), a read depth–based CNV calling algorithm for WGS tumor data.
Briefly, BIC-seq2 divides genomic regions into disjoint bins and counts uniquely aligned reads for each bin. It then combines neighboring bins into genomic segments with similar copy numbers iteratively based on Bayesian information criteria (BIC). We used
paired-sample CNV calling that takes a pair of samples as inputs and detects genomic regions with different copy numbers between
the two samples. We used a bin size of 100bp and a lambda of 3 (smoothing parameter for CNV segmentation). Segments were called
as copy gain or loss when their log2 copy ratios were larger than 0.2 or smaller than 0.2, respectively. These cutoffs were obtained
by comparing the proportion of amplifications and deletions in the EC TCGA study and adjusting the cutoffs to match the proportions
in our cohort. To further summarize the arm-level copy number change, we used a weighted sum approach (Vasaikar et al., 2019), in
which the segment-level log2 copy ratios for all the segments located in the given arm were added up with the length of each segment
being weighted.
Somatic Variant Calling
We called variants using paired tumor and blood normal from WXS data. Somatic variants were called by Strelka v.2 (Saunders et al.,
2012), MUTECT v.2 (Cibulskis et al., 2013), VarScan v.2.3.8 (Koboldt et al., 2012), and Pindel v.0.2.5 (Ye et al., 2009). We kept SNVs
called by any 2 callers among MUTECT v.2, VarScan v.2.3.8, and Strelka v.2 and indels called by any 2 callers among MUTECT v.2,
VarScan v.2.3.8, Strelka v.2, and Pindel v.0.2.5. For the merged SNVs and indels, we applied a 14X and 8X coverage cutoff for tumor
and normal, separately. We also filtered SNVs and indels by a minimal variant allele frequency (VAF) of 0.05 in tumors and a maximal
VAF of 0.02 in normal samples. Finally, we filtered any SNV which was within 10bp of an indel found in the same tumor sample.
We identified a total of 52,630 somatic mutations, of which 5,757 were indels and 46,873 were point mutations. Specifically, there
were 4,430 frameshift deletions, 1,035 frameshift insertions, 258 in-frame deletions, 34 in-frame insertions, 41,127 missense mutations, 4,580 nonsense mutations, 63 nonstop mutations, and 1,103 splice site mutations. We use MuSiC v0.4 in order to infer SMGs
based on background mutation rate, coverage, gene length, etc. (Dees et al., 2012).
We cataloged PTM-overlapping mutations (mutations located at most two amino acids away from a known PTM site) in all genes;
genes with the most overlapping mutations were PTEN, MUC16, CTNNB1, MKI67, and TP53. When restricting to only phosphosites
detected in our EC cohort, CTNNB1 had the most PTM-overlapping mutations.
Mutational Signatures
We use SignatureAnalyzer v0421-2017 (Tan and Févotte, 2013) in order to infer mutational signatures for our cohort. We identified 6
signatures, which were mapped to the 30 mutational signatures from the Stratton study (Alexandrov et al., 2013).
Methylation Analysis
The raw data from Illumina’s EPIC methylation arrays were available as IDAT files from the CPTAC consortium. The methylation
analysis was performed using the cross-package workflow ‘‘methylationArrayAnalysis.’’ Briefly, the raw data files (IDAT files) were
processed to obtain the methylated (M) and unmethylated (U) signal intensities for each locus. The processing step included an unsupervised normalization step called functional normalization that has been previously implemented for Illumina 450K methylation
arrays (Fortin et al., 2014). A detection p value was also calculated for each locus to capture the quality of detection at the locus
with respect to negative control background probes included in the array. Loci having common SNPs (MAF > 0.01) (as per dbSNP
build 132 through 147 via the UCSC snp132common track through snp147common track) were removed from further analysis.
Beta values were calculated as M/(M+U); that is, the fraction methylated for each locus. Beta values of loci whose detection
p values were > 0.01 were assigned values of NA in the output file. All loci were annotated with the annotation information from
‘MethylationEPIC_v-1-0_B2.csv’ from the zip archive ‘infinium-methylationepic-v1-0-b2-manifest-file-csv.zip’ from https://www.
illumina.com through the IlluminaHumanMethylationEPICanno.ilm10b2.hg19 package on Bioconductor. For downstream integrated
analysis, we focused only on the methylation levels (represented as beta values) of the probes located both in the CpG island and the
promoter (including 50 UTR) regions. The gene-level methylation was derived by averaging these probe-level methylation values.
Microsatellite Instability Prediction
We used 5 criteria to predict microsatellite instability status: mutation load, mismatch repair (MMR) gene mutation status, MSIsensor
(v0.2) score, MSMuTect (version 1.0) score, and MLH1 methylation. K-Means clustering method with 2 cluster centers was applied to
mutation load, MSIsensor, MSMuTect, and MLH1 methylation. For each tool, samples in the higher group were assigned as MSI-H.
Six MMR genes, MLH1, MLH3, MSH2, MSH3, MSH6, and PSM2, were considered in the analysis. Samples with a mutation in any of
these genes were labeled as MSI-H for the MMR gene criterion. A sample was officially called MSI-H if it was predicted to be MSI-H
by no fewer than 3 of 5 methods (Table S3).
Copy Number Classification
The copy number subtypes were mainly characterized by CNV deletion events. A sample was defined as CNV-high more than 10% of
its genome was deleted, regardless of the number of CNV-independent events. However, a CNV event, defined by the minimal copy
number change (in log2 scale), is dependent on the tumor purity. A sample with low purity will have a smaller change than samples
with high purity. Here we defined the per-sample threshold as 0.3 times the sample purity. Purity was estimated using ABSOLUTE
(Carter et al., 2012).
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TCGA Subtype Classification
TCGA identified four subtypes of endometrial cancer: POLE, MSI, CNV-high, and CNV-low. We replicated this subtyping for the samples in our study.
The MSI subtype consists of all samples called MSI-H, as described in the Microsatellite Instability Prediction section.
To identify the POLE subtype, which has better survival than other subtypes, we looked for samples with mutations in the POLE
exonuclease domain (McConechy et al., 2016; Stelloo et al., 2015; Talhouk et al., 2017). There were 8 samples carrying exonuclease
domain mutations (EDM) in the cohort, including 7 missense mutations and 1 splice site mutation from the sample C3L-01253. However, this sample failed to pass the criteria [CA] signature > 20% and [CG] signature < 3%. Thus, seven samples were classified
as POLE.
Samples identified as having high CNV, as described in the Copy Number Classification section, were assigned to the CNV-high
subgroup. All remaining samples not classified as MSI, POLE, or CNV-high were classified as CNV-low.
HotSpot3D
We conducted 3D structural clustering using HotSpot3D v1.8.2 with recurrence as the vertex type and a clustering distance of 10Å
(Niu et al., 2016).
JAK1 Mutation Determination
Gene level microsatellite instability (MSI) events from MSMuTect and gene mutation calling results were integrated to determine the
JAK1 MS insertion/deletion status. There were nine MSI events from eight samples identified by both MSMuTect and mutation calling. Three JAK1 MSI events, which failed to pass filtering steps from MSMuTect but had mutation calling evidence, were also classified as MS insertion/deletion.
RNA Quantification & Analysis
RNA Quantification and Circular RNA Prediction
The Hg38 reference genome and RefSeq annotations were used for the RNaseq data analysis. They were downloaded from the
UCSC table browser. First, CIRI (v2.0.6) was used to call circular RNA with default parameters and BWA (version 0.7.17-r1188)
was used as the mapping tool. The cutoff of supporting reads for circRNA was set to 10. Then we used a pseudo-linear transcript
strategy to quantify gene and circular RNA expression (Li et al., 2017). In brief, for each sample, linear transcripts of circular RNAs
were extracted and 75bp (read length) from the 30 end was copied to the 50 end. The modified transcripts were called pseudo-linear
transcripts. Transcripts of linear genes were also extracted and mixed with pseudo-linear transcripts. RSEM (version 1.3.1) with
Bowtie2 (version 2.3.3) as the mapping tool was used to quantify gene and circular RNA expression based on the mixed transcripts.
After quantification, the upper quantile method was applied for normalization. The normalized matrix was log2-transformed and
separated into gene and circular RNA expression matrices.
miRNA-Seq Data Analysis
Adapters of miRNaseq reads were trimmed using TRIMMOMATIC (version 0.38). The following constraints were used during trimming: 1) HEADCROP and TAILCROP were set to 4bp; 2) Average read quality was set to 30; 3) Average base quality was set to
20 with a sliding window of 10bp; 4) Trimmed reads shorter than 15 nucleotides in length were excluded from further analysis. Remaining reads were then mapped to the human genome hg38 using BWA aln, allowing 0 mismatch and up to 10 mappings. 3 bp
extension / shorten were allowed in both upstream and downstream regions of mature miRNA annotation to accommodate inaccurate processing of precursor miRNAs. Multiple aligned reads were equally distributed in counting. Then read counts were converted
to RPM (reads per million) values using (raw counts) 3 106 / (total count), where total count is the number of reads aligned to mature or
precursor miRNAs.
miRNA Binding Site Prediction
RNA22 was used to predict miRNA binding sites on circRNAs with default parameters (Miranda et al., 2006). The circRNA
circCDR1as, which has 74 confirmed miR-7 binding sites, was used to determine the p value cutoff (Memczak et al., 2013).
RNA22 reported 49 potential binding sites of miR-7 on this circRNA. The third quartile of p values, 0.0207, was used as the cutoff
for miRNA binding sites prediction. miRNAs with binding sites but without miRNA activity scores (see Inferred Immune, EMT,
APM, and miRNA Activity Scores) were excluded from further analysis. After the filtering, there were binding sites for 36 miRNAs
from 16 of 35 QKI regulated circRNAs (Figure S4C).
Pathway Activity
The PROGENy R package was applied to the log2 transformed RSEM mRNA matrix to estimate activity of 11 cancer related pathways: EGFR, Hypoxia, JAK/STAT, MAPK, NFkB, PI3K, TGFb, TNFa, Trail, VEGF, p53 (Schubert et al., 2018).
MS Data Interpretation
Quantification of TMT Global Proteomics Data
LC-MS/MS analysis of the TMT10-labeled, bRPLC fractionated samples generated a total of 408 global proteomics data files. The
Thermo RAW files were processed with mzRefinery to characterize and correct for any instrument calibration errors, and then with
MS-GF+ v9881 (Gibbons et al., 2015; Kim and Pevzner, 2014; Kim et al., 2008) to match against the RefSeq human protein sequence
database downloaded on June 29, 2018 (hg38; 41,734 proteins), combined with 264 contaminants (e.g., trypsin, keratin). The partially
tryptic search used a ± 10 ppm parent ion tolerance, allowed for isotopic error in precursor ion selection, and searched a decoy
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database composed of the forward and reversed protein sequences. MS-GF+ considered static carbamidomethylation
(+57.0215 Da) on Cys residues and TMT modification (+229.1629 Da) on the peptide N terminus and Lys residues, and dynamic
oxidation (+15.9949 Da) on Met residues for searching the global proteome data.
Peptide identification stringency was set at a maximum false discovery rate (FDR) of 1% at peptide level using PepQValue < 0.005
and parent ion mass deviation < 7 ppm criteria. A minimum of 6 unique peptides per 1000 amino acids of protein length was required
for achieving 1% at the protein level within the full dataset. Inference of parsimonious protein set resulted in the identification of a total
of 12,153 protein groups covering 11,099 genes.
The intensities of all ten TMT reporter ions were extracted using MASIC software (Monroe et al., 2008). Next, PSMs passing the
confidence thresholds described above were linked to the extracted reporter ion intensities by scan number. The reporter ion intensities from different scans and different bRPLC fractions corresponding to the same gene were grouped. Relative protein abundance
was calculated as the ratio of sample abundance to reference abundance using the summed reporter ion intensities from peptides
that could be uniquely mapped to a gene. The pooled reference sample was labeled with TMT 126 reagent, allowing comparison of
relative protein abundances across different TMT-10 plexes. The relative abundances were log2 transformed and zero-centered for
each gene to obtain final relative abundance values.
Small differences in laboratory conditions and sample handling can result in systematic, sample-specific bias in the quantification
of protein levels. In order to mitigate these effects, we computed the median, log2 relative protein abundance for each sample and recentered to achieve a common median of 0.
Evaluation of TMT Proteomics Data
Coupled with extensive fractionation and tandem affinity enrichment of the phosphopeptides and acetylated peptides, our 10-plex
TMT-based MS/MS workflow provided comprehensive proteomic coverage, confidently identifying a total of 12,153 proteins (11,099
genes), 73,212 phosphosites, and 10,862 lysine acetylation sites across all tumors and an average of 10,088 proteins (9,765 genes),
29,710 phosphosites, and 3,821 lysine acetylation sites per tumor (Table S2). Stable longitudinal performance and low technical
noise of the integrated proteomics platform were demonstrated by repeated interspersed analyses of QC samples (Figures S1B
and S1C). Principal component analysis clearly separated the tumors and normal endometrium tissue based on the TMT global proteome, phosphoproteome, or acetylome data and no batch effect was observed in the TMT plexes (Figures S1D–S1F) (Wen et al.,
2017). Steady-state mRNA and protein abundance showed a strong positive correlation (median 0.48) (Figure S1G). This average
correlation was higher than the previous reported CPTAC colorectal (r = 0.23), breast (r = 0.39), and ovarian (r = 0.45) mRNA-protein
correlations. Around 78% of all mRNA-protein pairs across the 95 samples showed significant correlation (adj p value < 0.01).
Eight normalization methods were tested for global proteomics matrix: 1) median normalization followed by batch correct; 2) median normalization; 3) Median polish followed by batch correction; 4) median polish; 5) subtracted mean for each batch; 6) median
normalization; 7) filtering missing by batch followed by median normalization and batch correct; 8) filtering missing by batch followed
by median normalization. The 50% missing values cutoff for the whole cohort was used for methods 1-6 and the same cutoff for each
TMT batch was used for methods 7-8. The correlation in abundance between proteins from the same protein complex was used as a
criterion to evaluate these methods and the performances are shown in Figure S1H. Methods 4 and 8 have the same performance
and outperform other methods by the same criterion. However, method 4 has better classification between serous and endometrioid.
In sum, method 4 has the best performance for proteomics data.
Similarly, six normalization methods were applied to the phosphoproteomics matrix: 1) median normalization with factor from proteomics data followed by batch correction; 2) median normalization with factor from proteomics data; 3) median normalization followed by batch correction; 4) median normalization; 5) median polish followed by batch correction; 6) median polish. The 50%
missing values cutoff for the whole cohort was used for the analysis. The correlation between sites (substrates) from the same kinase
was used as the criterion to evaluate these methods and performances are shown in Figure S1I. Method 6 outperforms other
methods by the criterion.
Quality Control via Machine Learning
We also selected three clinically distinct phenotypes with at least 10 samples per group and compared the utility of multi-omics data
to identify the phenotype of individual tumors using machine learning. Global proteomics data performed as well as most other transcriptomic and genomic data to distinguish between the histological serous and endometrioid subtypes (Figure S1J). Similarly in
identification of samples with MSI, proteomics, RNA, and methylation data demonstrated comparable ability (Figure S1K). While
these phenotypes are visually or genomically distinct, low-grade FIGO stage 1B and 1A samples can be hard to differentiate,
although pre-surgical classification determines the necessity of lymphadenectomy (Zhu et al., 2017). Proteomics data performed
significantly better (median AUROC of 0.73) than any other data type in predicting whether a sample was stage 1B or stage 1A
(Figure S1L).
Creation of a Patient-Specific Protein Sequence Database
The proteogenomic database tool pyQUILTS (Ruggles et al., 2016), available at http://quilts.fenyolab.org, was used to incorporate
the germline and somatic single nucleotide variants (SNVs), RNA-seq predicted junctions and fusion genes into a searchable protein
database. The human RefSeq protein database (downloaded 2018/06/29) was used as a reference for the hg38 proteome and
genome.
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Protein-Peptide Identification and Quantification with Patient-Specific Sequence Database
Protein sequences output from pyQUILTS were digested in-silico to generate all unique tryptic peptides with up to one missed cleavage allowing for N-terminal methionine cleavage. Isoleucine residues were then replaced with leucines to avoid I/L variants. The
CPTAC3 reference proteome (along with the human proteome downloaded from UniProt on 2016/07/29) were similarly processed
to remove any possible reference peptides from the list of candidates, resulting in 5,295,726 unique peptide sequences.
Candidate peptides were submitted to the Pepcentric search engine (http://pepcentric.arsci.com:8080/) for peptide-centric
searching against the whole proteome EC dataset. For each peptide, the PSM with the lowest expectation value was selected as
a representative and expectation values were converted to p values using a permutation test with twenty million randomly-permuted
decoy peptides. TMT channel intensities were extracted from each spectra and intensities were summed across all PSMs associated
with a particular candidate peptide sequence for quantitation at the sample level.
A very stringent thresholding was performed to minimize the chance of false positive peptide identification. First, all peptides with a
q-value > 0.05 were removed, as were any peptides which had a lower expectation value than the best peptide in the closed (exact
match) or open (allowing for one modification) UniProt search. Next, all matches with a TMT intensity below 20,000 or lower than 80%
of the max TMT value for that peptide were removed, as these were more likely to be overflow from other channels. After that, all
peptides with genomic or peptide evidence in more than a third of the dataset were removed, the rationale being that these would
not have been rare variants and were therefore likely false positives that should have been classified as a reference peptide. Finally, all
peptides that lacked genomic evidence in any of the samples in which the peptide was found were removed. Although this thresholding method is likely to remove many true positives, the objective was to be as certain as possible about the peptides that
remained.
Quantification of Phosphopeptides
Phosphopeptide identification for the 204 phosphoproteomics data files were performed as in the global proteome data analysis
described above (e.g., peptide level FDR < 1%), with an additional dynamic phosphorylation (+79.9663 Da) on Ser, Thr, or Tyr residues. The phosphoproteome data were further processed by the Ascore algorithm (Beausoleil et al., 2006) for phosphorylation site
localization, and the top-scoring sequences were reported. For phosphoproteomic datasets, the TMT-10 quantitative data were not
summarized by protein, but left at the phosphopeptide level. All peptides (phosphopeptides and global peptides) were labeled with
TMT-10 reagent simultaneously. Separation into phospho- and non-phosphopeptides using IMAC was performed after the labeling.
Thus, all the biases upstream of labeling are assumed to be identical between global and phosphoproteomics datasets. Therefore, to
account for sample-specific biases in the phosphoproteome analysis, we applied the correction factors derived from mediancentering the global proteomic dataset.
Quantification and Analysis of Acetylated Peptides
Acetylated peptide identification for the 68 acetylome data files were performed as in the global proteome data analysis described
above, with additional dynamic acetylation (+42.0105 Da) and carbamylation (+43.0058 Da) on Lys residues. The acetylation site
localization, protein inference, and quantification of the acetylome data were performed in identical fashion as in the phosphoproteome data.
Theoretically, the IMAC-enriched phosphopeptide sample (or, less likely, the acetylpeptide sample enriched by IP from the IMAC
flow-through) could still contain the dual-modified peptides. However, it is currently difficult to use the protein sequence database
searching algorithms to identify such peptides, because a rather large number of ‘‘dynamic’’ modifications need to be considered
during the database search (dynamic phosphorylation on Ser, Thr, or Tyr residues, dynamic acetylation and carbamylation on Lys
residues, dynamic oxidation on Met residues, and dynamic deamidation at the N-terminal), leading to unreliable estimation of the
FDR. As a result, this was not pursued in this study.
Histone acetylation values from one functional site but encoded for different histone genes paralogs were averaged. For example,
reported peptides HIST1H2BH_K12 and HIST1H2BD_K12 were averaged to obtain the acetylation value for the H2B_K12 site. To
test the association between HATs/HDACs protein and acetylation levels of histone sites, we fitted Lasso regression model with
HATs/HDACs and histone protein expression as independent variables and a histone acetylation site as a dependent variable. Lasso
regression has been chosen because it takes expression of all enzymes into account simultaneously and is insensitive to highly correlated dependent variables. We performed 300 bootstraps with 80% training data and 20% testing data, and reported averaged
coefficients returned by the model across 300 iterations. Differentially acetylated sites between tumor and enriched normal endometrium samples were found using Wilcoxon rank sum test with at least 6 samples in both groups. The p values were FDR-corrected
using the Benjamini-Hochberg procedure. Upregulated sites were defined as ones with FDR-corrected p value < 0.05 and median
difference > = 0.4, while the corresponding protein change was either not significant (FDR > 0.05), or median difference < 0.5.
Other Proteogenomic Analyses
Phenotype Prediction
We used XGBoost (v0.81) (Chen and Guestrin, 2016) to develop models for predicting clinical phenotypes using seven types (mutation, copy number alteration, methylation, mRNA abundance, miRNA abundance, protein abundance, and phosphoprotein abundance) of omics data. For each data type, we first split the data into training and test (80%/20%) sets. We then tuned the model’s
hyperparameters to improve its generalization performance using the training set. For XGBoost, there are two important parameters:
the maximum number of nodes allowed from the root to the farthest leaf of a tree, max_depth and the number of trees in the forest,
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n_estimators. We used grid search with cross validation to find the best parameters, using the area under the receiver operating characteristic (AUROC) as the evaluation metric. A grid of 4 different n_estimators values (10, 20, 50, 100) and 5 different max_depth
values (2, 4, 6, 8, 10) was created and each combination was evaluated using 3-fold cross validation within the training data. Finally,
we fit a new model on the whole training set with the parameters that yielded the best cross validation performance. For each data
type, we repeated the entire procedure 10 times to capture the performance variation.
Mutation Impact on the Proteome and Phosphoproteome
We aggregated a set of interacting proteins (e.g., kinase/phosphatase-substrate or complex partners) from Omnipath (downloaded
on 03/29/18) (Türei et al., 2016), DEPOD (03/29/18) (Duan et al., 2015), CORUM (downloaded 06/29/18) (Ruepp et al., 2008), Signor2
(10/29/18) (Perfetto et al., 2016), and Reactome (11/01/18) (Fabregat et al., 2018). We focus our analyses on 18 EC SMGs previously
reported in the literature (ARID1A, CTCF, CTNNB1, FBXW7, FLNA, GENE, HUWE1, INPPL1, JAK1, KMT2B, KMT2D, KRAS,
MAP3K4, PIK3CA, PIK3R1, PTEN, RPL22, and TP53) (Bailey et al., 2018; Kandoth et al., 2013).
For each interacting protein pair, we split samples with and without mutations in partner A and compare expression levels (both
protein and phosphosites) both in cis (partner A) and in trans (partner B), calculating a median difference in expression and testing
for significance with the Wilcoxon rank sum tests, with the Benjamini-Hochberg multiple test correction. We further refine the list of
trans interactions by filtering proteins that are not part of oncogenic processes identified in TCGA (Sanchez-Vega et al., 2018).
Fusion Calls
We use three callers to call consensus fusion/chimeric events in our samples (STAR-Fusion, INTEGRATE, and ericscript). Calls by
each tool using tumor and normal RNA-Seq data are then merged into a single file and extensive filtering is done. As STAR-Fusion
has higher sensitivity, calls made by this tool with higher supporting evidence (defined by fusion fragments per million total reads, or
FFPM > 0.1) is required, or a given fusion must be reported by at least 2 callers. We then remove fusions present in our panel of blacklisted or normal fusions, which include uncharacterized genes, immunoglobin genes, mitochondrial genes, and others, as well as fusions from the same gene or paralog genes (https://www.genenames.org/cgi-bin/statistics) and fusions reported in TCGA normal
samples (Gao et al., 2018), GTEx tissues (reported in STAR-Fusion output), and non-cancer cell studies (Babiceanu et al., 2016).
Finally, we remove normal fusions from the tumor fusions to curate the final set.
PTMcosmos
We gathered 438,983 human PTM sites from PTMcosmos (https://ptmcosmos.wustl.edu/). PTM sites from PTMcosmos were
retrieved from UniProt Knowledge Base (UniProtKB) version 2019.01, PhosphoSitePlus (snapshot on the date 2018-02-14), and
CPTAC phosphorylation and acetylation mass spectrometry data. A PTM site from UniProtKB was included if it was reported in
at least one publication or by sequence similarity. A PTM site from PhosphoSitePlus was included if it was reported in at least
one publication or validated internally by Cell Signaling Technology. A PTM site from CPTAC experiments was included if it was detected in at least one of the samples.
We used genome-wide point mutations (n = 46,031) and PTMs from the PTMcosmos database (n = 363,670), in order to account
for both detected and undetected PTM sites in our cohort. We obtained 5,120 (11% of point mutations) PTM-overlapping mutations:
1,083 directly within the PTM site and 4,037 within two residues of the PTM site.
Inferred Immune, EMT, APM, Wnt Pathway, and miRNA Activity Scores
All scores were inferred by single sample gene set enrichment analysis (ssGSEA) method from the GSVA R package (Barbie et al.,
2009; Hänzelmann et al., 2013). The EMT gene signature set is from (Mak et al., 2016), immune signatures are from (Charoentong
et al., 2017), and the KEGG antigen processing and presentation pathway gene set is used as the APM signature. The KEGG Wnt
Signaling Pathway gene set was used to analyze the Wnt pathway signatures for our CTNNB1-mutated and WT tumors. mRNA
expression was used to infer EMT and immune scores and protein abundance was used to infer the APM score. Targets of miRNAs
were downloaded from the miRNA targets database miRTarBase and only the miRNA/target pairs with strong experimental evidence
were retained (Chou et al., 2018). miRNA target sets with fewer than 10 genes were removed. The -log2 transformed ssGSEA score
was used as the miRNA activity score.
TMB and APM Subtyping
The value of log2 transformed variants per million bp was used as TMB for the analysis. The k-means algorithm with two centers was
applied to TMB and APM Z-score independently. The initial cluster centers were set as the mean values of the top 5 and bottom 5
samples. The classification results reported by the k-means algorithm were directly used for tumor subtyping.
Differential Proteomic Analysis
TMT-based global proteomic, phosphoproteomic, and acetylation data were used to perform pairwise differential analysis between
groups of samples. A Wilcoxon rank-sum test was performed to determine differential abundance of proteins and PTMs. At least four
samples in both groups were required to have non-missing values and the p value was adjusted using the Benjamini-Hochberg
method. For phosphorylation markers in each genomic subtype, the adjusted p value for the protein change was required to
be > = 0.05. Over-representation analysis of Wikipathways genesets was performed with the proteins containing the phosphorylation
markers. Pathways were considered significant with FDR < 0.05.
Kinase Activity Analysis
Phosphoproteomic data for unique thirteenmer sequence motifs (±6 amino acids from the phosphorylated site) were combined by
median for each sample. Differential abundance was performed as above and thirteenmers were ranked by the signed log p value.
Pre-ranked GSEA was performed using WebGestaltR (Liao et al., 2019) with substrates collected from PhosphoSitePlus, Swiss-Prot,
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and HPRD. A minimum of 10 substrates per kinase was required. Kinases were considered significantly differentially active with an
FDR < 0.05.
Phosphoproteome Outlier Analysis
We performed outlier analysis using the BlackSheep package (Blumenberg et al., 2019). Briefly, we calculated the median and interquartile range (IQR) values for each phosphopeptide using TMT-based global phosphoproteomic data. Outliers were defined for
each phosphopeptide as any value higher or lower than the median plus or minus 1.5x IQR, respectively. Phosphopeptide data
was then aggregated into genes by summing outlier and non-outlier values per sample. Outlier counts were used to determine enriched genes in a group of samples. First, genes without an outlier value in at least 30% of samples in the group of interest were
filtered out. Additionally, genes with a lower average fraction of outlier sites in the group of interest than in the rest of the samples
were also filtered out. Then the group of interest was compared to the rest of the samples using a Fisher’s exact test on the sum
of outlier and non-outlier values per group. Resulting p values were corrected for multiple comparisons using the Benjamini-Hochberg correction. Druggability was determined for each gene using the drug-gene interaction database (DGIdb) (Cotto et al., 2018).
DNA Damage Response Score
Phosphoproteome outlier analysis was used to construct a DNA damage response (DDR) score. To isolate well-established phosphorylation substrates during DNA damage, we focused on genes listed in Table S3 from (Matsuoka et al., 2007). These proteins had
SQ/TQ sites that were found to be phosphorylated by ATM, ATR or DNAPK in response to DNA damage, and had also been identified
in previous literature as phosphorylation substrates. To calculate the DDR score, we standardized the fraction of phosphosites per
gene across samples, and averaged values of this subset of genes per sample. We defined DDR-high samples as all samples with a
DDR score more than 1.5 IQR above the median DDR score.
Cancer/Testis Antigens
We downloaded cancer/testis antigens from CTdatabase (http://www.cta.lncc.br) (Almeida et al., 2009). The database consists of
269 cancer-testis antigens with carefully curated and annotated literature-derived information. The CT antigens present in the proteomics dataset were selected and z-scores were calculated for each sample compared to the abundance distribution in all normal
samples. Tumor samples with a z-score greater than 3 were considered to have high expression of that CT antigen. Only CT antigens
with high abundance in at least 10% of the tumors samples were retained.
Variant Peptide Identification and Neoantigen Prediction
We used NeoFlow (https://github.com/bzhanglab/neoflow) for neoantigen prediction. Specifically, Optitype (Szolek et al., 2014) was
used to find human leukocyte antigens (HLA) in the WXS data. Then we used netMHCpan (Jurtz et al., 2017) to predict HLA peptide
binding affinity for somatic mutation–derived variant peptides with a length between 8-11 amino acids. The cutoff of IC50 binding affinity was set to 150 nM. HLA peptides with binding affinity higher than 150 nM were removed. Variant identification was also performed at both mRNA and protein levels using RNA-Seq data and MS/MS data, respectively. To identify variant peptides, we
used a customized protein sequence database approach (Wang et al., 2012). We derived customized protein sequence databases
from matched WXS data and then performed database searching using the customized databases for individual TMT experiments.
We built a customized database for each TMT experiment based on somatic variants from WXS data. We used Customprodbj
(https://github.com/bzhanglab/customprodbj) for customized database construction. MS-GF+ was used for variant peptide identification for all global proteome, phosphorylation and acetylation data. Results from MS-GF+ were filtered with 1% FDR at PSM level.
Remaining variant peptides were further filtered using PepQuery (http://www.pepquery.org) (Wen et al., 2019) with the p value
cutoff % 0.01. The spectra of variant peptides were annotated using PDV (http://www.zhang-lab.org/) (Li et al., 2019) and the annotated spectra are shown in Table S7.
mRNA and Protein and Protein and Phosphoprotein Correlation
To compare mRNA expression and protein abundance across samples we focused on the 9575 genes with RNA-Seq based RSEM
measurement and proteomics data. The analyses were carried out on normalized data where RSEM count data was upper-quartile
normalized, while proteomics data was quantile normalized. Correlation was performed by Spearman’s correlation method. Both
correlation coefficient and p value were computed. Furthermore, p values were adjusted by the Benjamini–Hochberg procedure.
The same procedure of mRNA-protein correlation was applied to protein-phospho cis pairs. Sorted Spearman’s correlation coefficients were further used for ssGSEA analysis with default settings.
SCNA Cis and Trans Effect Identification
The correlations between copy number (gene level), RNA expression, and protein expression were performed using Spearman’s rank
correlation for 9377 genes with quantified data from all three platforms. We defined the SCNA cis effect as the significant association
(FDR < 0.01, Spearman’s rank test) between a given copy number and the gene expression at both protein and RNA levels from the
same genome loci, and the SCNA trans effect as the significant association (FDR < 0.01, Spearman’s rank test) between a given locus
and global gene expression (Zhang et al., 2014).
Anti-p53 Pathway Driver Gene Prioritization
The p53 pathway activity was inferred from known p53 transcription targets (MSigDB INGA_TP53_TARGETS, (Inga et al., 2002)) using ssGSEA (Barbie et al., 2009) implemented in the R package GSVA (Hänzelmann et al., 2013). In order to prioritize the genes whose
protein expression is associated with p53 pathway activity, we used the following linear regression:
p53_pathway_score = b1 X IðTP53 mutationÞ + b2 X ProExprs
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Where the I(TP53 mutation) denotes the indicator function (1 if TP53 is mutated or 0 if TP53 is wild type), and ProExprs denotes the
protein expression of the given gene. The association between protein expression and p53 activity was ranked based on the
statistical significance of b2. Furthermore, to summarize whether a given gene set (e.g., all qualified genes in 1q) was significantly
associated with p53 activity, the ranking metric derived above for all the genes and the gene set was tested using the GSEA method
implemented in the R package fgsea (Sergushichev, 2016).
DATA AND CODE AVAILABILITY
Processed data tables are available in Table S2. Data used for the manuscript are also available through a Python package called
‘cptac’ (https://pypi.org/project/cptac/, install via pip) to allow programmatic access and LinkedOmics (http://www.linkedomics.
org/) (Vasaikar et al., 2018) to allow association and pathway analysis. Raw genomic data is available from the Genomic Data Commons (https://gdc.cancer.gov/) or upon request from dbGaP (https://www.ncbi.nlm.nih.gov/gap/, phs001287) and proteomic data is
available via the CPTAC Data Portal (https://cptac-data-portal.georgetown.edu/cptacPublic/).
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Supplemental Figures

Figure S1. Integrated Proteomics Workflow and Longitudinal Data Generation Quality Control, Related to STAR Methods
(A) TMT-10 based global proteome, phosphoproteome, and acetylome analysis workflow. The EC tumors and normal tissues were analyzed in 17 TMT 10-plex
experiments, each with 9 study samples and a common internal reference sample created by pooling all study samples (equal contribution). The TMT10-labeled
samples were then fractionated, split (with 5% peptide mass analyzed directly for global proteome), and subjected to tandem enrichment of phosphopeptides
and acetylated peptides. Peptides were detected and quantified using information from the TMT-10 MS/MS spectra.

(legend continued on next page)

(B) Distribution of sequence coverage of the identified proteins with tryptic peptides detected by MS/MS in each TMT-10 plex; whiskers show the 5–95
percentiles.
(C) Robust and precise proteomics platforms. Longitudinal performance was tested by repeated proteome, phosphoproteome and acetylome analysis of aliquots
of the same patient-derived xenograft QC samples in standalone TMT-10 plexes, along with the EC study samples; scatterplots and Pearson correlations
comparing individual replicate measurements are shown.
(D–F) Principal component analysis separated the tumors and normal endometrium tissue based on the TMT global proteome, phosphoproteome, or acetylome
data and no batch effect was observed in the TMT plexes.
(G) mRNA and protein abundance showed a strong positive correlation (median 0.48). Around 78% of all mRNA-protein pairs across the 95 samples showed
significant correlation.
(H and I) Evaluation of proteomics and phosphoproteomics normalization methods by correlation in abundance between proteins from the same protein complex
or same substrates.
(J–L) Multi-omics data was used to identify the phenotype of individual tumors using machine learning. Global proteomics data performed as well as most other
transcriptomic and genomic data to distinguish between the histological serous and endometrioid subtypes. It performances better than other platforms in
predicting FIGO stage 1B and 1A samples which are hard to differentiate.

Figure S2. Profiles of Significantly Mutated Genes, Related to Figure 1
(A) Mutation, CNA, RNA, protein, and phosphoprotein profiles of several significant genes.
(B) Endometrial cancer has distinct microsatellite indel patterns compared to colon cancer. JAK1 microsatellite indels are unique for EC compared to colon
cancer as reported before.
(C) JAK1 mutation promotes grade of MSI-H tumors in both CPTAC and TCGA cohorts.

Figure S3. Mutation Effects on Protein and Phosphoprotein Levels, Related to Figure 2
(A) Missense and truncation mutations and their respective effects without hyper- and ultramutated samples.
(B) Mutations and phosphosites mapped to the CTNNB1 gene. Hotspot3d mutations that target the known exon 3 locus in our cohort are shown in purple.

(legend continued on next page)

(C) CTNNB1 mutated tumors have higher phosphorylation in APC site S2106 (left) and S2278 (right).
(D) CTNNB1 mutated tumors have higher phosphorylation in AXIN1 site S77 (left) and S493 (right).
(E) Samples with CTNNB1 overlap mutations have higher CTNNB1 protein levels but not significantly different APC protein levels.
(F) There is a significant difference in Wnt signaling pathway signatures between CTNNB1 hotspot mutants and WT patients.
(G) The upregulation of protein abundance of selected genes are correlated with P53 mutated types
(H) TP53 mutation types specific protein abundance of AURHA, CDK1, STK11, TP53 in Ovarian cancer.

Figure S4. Pathway, Histone, and SMG Relationships to Acetylation, Related to Figure 3
(A) KEGG pathways enriched in acetylated genes in our cohort.
(B) Histone protein levels and acetylation levels of specific histone sites. We detect four clusters of samples with differential H2B and H3 and H4 acetylation levels.

(legend continued on next page)

(C) Associations between histone acetylases and deacetylases and histone acetylation levels. We generally observe positive associations with H2B sites and
negative associations in H3 and H4 sites.
(D) Relationship of CTNNB1 hotspot mutants and acetylation levels of key acetylation-related enzymes.
(E) WNT pathway genes were upregulated in samples with high H2B acetylation.
(F) FOXA2 acetylation to be upregulated in the CNV-Low subtype compared to the CNV-High subtype.

Figure S5. Multi-omic Analysis Reveals DNA Methylation and Somatic Copy Number Alteration Drivers, Related to Figure 4
(A) Global DNA methylation analysis reveals higher genome-wide CpG island DNA methylation in MSI samples. Shown are the top 500 genes with most variable
DNA methylation levels across the cohort.
(B) Heatmap showing the association between DNA methylation of MLH1 and mismatch repair (MMR) defects and the association between DNA methylation of
HOX genes and double strand DNA break (DSB). Pearson correlation coefficients were shown for the associations of indicated molecular phenotypes. *p < 0.001,
**p < 0.0001.

(legend continued on next page)

(B) The overall copy number landscape was mostly consistent with the TCGA findings. The CNV-high samples had a high number of SCNAs and endometrioid
samples had much fewer.
(C) The global protein expression positively associated with 3q amplification implicated genes involved in DNA replication and cell cycle pathways. On the other
hand, the most significant pathways impacted by 4q loss include cytoskeleton and cilium assembly.
(D) A significant anticorrelation was found between SETDB1 protein level and TNFRSF10B RNA expression.

Figure S6. Proteomics Data Identifys Putative EMT Regulation via circRNA, Related to Figure 5
(A) The top 10 most abundant identified circRNAs in the cohort, including circHIPK3 and circDOCK1, which are known to regulate cell growth and serve as cancer
biomarkers.
(B) Significant positive correlations were found between QKI protein abundance and the EMT marker ZEB1.

(legend continued on next page)

(C) Significant positive correlations were found between QKI protein abundance and the EMT marker ZEB2.
(D) There are 36 predicted miRNAs binding sites from 16 QKI regulated circRNAs (p < 0.0207).
(E–I) Correlations between QKI mRNA expression and regulator miRNA activity and QKI mRNA expression and regulator miRNA abundance. While the predicted
activity of these miRNAs showed strong negative correlations with QKI abundance, their abundance was not negatively correlated with QKI mRNAs.
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Figure S7. Proteomic Markers of Clinical and Genomic Tumor Subtypes, Related to Figure 6
(A) Correlation between significant differential abundance change in four data types in MSI versus MSS samples.
(B) Correlation between significant differential abundance change in four data types between samples with serous and endometrioid histological type.
(C) Correlation between significant differential abundance change in four data types between CNV-high and CNV-low endometrioid samples.
(D) Heatmap of MLH1, PMS1, and PMS2 RNA, proteomic, and PTM data.
(E) Heatmap showing each sample’s phosphorylation status for the set of phosphoproteins used to determine DDR score.
(F) Scatterplot of DDR score against PLK1 protein abundance.
(G) Scatterplot of DDR score against CHEK2-S163 phosphoprotein abundance.

(legend continued on next page)

(H) Scatterplot of DDR score against G2M score.
(I) Venn diagram of the number of phosphoproteins differentially expressed in CNV-high endometrioid and serous samples.
(J) Kinase activity in CNV-high endometrioid samples compared to CNV-low endometrioid samples. Red points indicate kinases targeted by an FDAapproved drug.

